Sciclone Pharmaceuticals (SCLN) 10-K 9 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 07, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	scln
Entity Registrant Name	SCICLONE PHARMACEUTICALS INC
Entity Central Index Key	880,771
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		51,505,795
Entity Public Float			$ 670,206,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 134,395	$ 101,403
Restricted cash in escrow for SEC settlement (Note 15)		12,826
Accounts receivable, net of allowances of $0 and $594 as of December 31, 2016 and 2015, respectively	41,510	39,363
Inventories	16,587	10,976
Prepaid expenses and other current assets	3,241	3,654
Deferred tax assets		299
Total current assets	195,733	168,521
Property and equipment, net	2,002	2,651
Investment in third party (Note 5)	794
Goodwill	30,838	32,979
Other assets	12,531	12,468
Total assets	241,898	216,619
Current liabilities:
Accounts payable	3,645	4,495
Accrued and other current liabilities	22,796	32,151
Deferred revenue		174
Total current liabilities	26,441	36,820
Other long-term liabilities	92	87
Commitments and contingencies (Notes 9 and 15)
Stockholders' equity:
Preferred stock; $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock; $0.001 par value; 100,000,000 shares authorized; 51,236,952 and 49,533,835 shares issued and outstanding as of December 31, 2016 and 2015, respectively	51	50
Additional paid-in capital	304,599	296,086
Accumulated other comprehensive income (loss)	(1,520)	2,070
Accumulated deficit	(87,765)	(118,494)
Total stockholders' equity	215,365	179,712
Total liabilities and stockholders' equity	$ 241,898	$ 216,619

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts	$ 0	$ 594
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	51,236,952	49,533,835
Common stock, shares outstanding	51,236,952	49,533,835

Consolidated Statements Of Inco

Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net revenues:
Product sales, net	$ 155,937	$ 154,329	$ 131,973
Promotion services	4,159	2,928	2,817
Total net revenues	160,096	157,257	134,790
Operating expenses:
Cost of product sales	22,898	22,348	23,002
Sales and marketing	54,704	53,961	48,477
Research and development	15,078	12,314	14,581
General and administrative	34,181	27,897	22,746
SEC settlement expense (Note 15)		10,826
Total operating expenses	126,861	127,346	108,806
Income from operations	33,235	29,911	25,984
Non-operating income (expense):
Interest and investment income	1,062	869	161
Interest and investment expense			(48)
Other income (expense), net	(164)	(510)	280
Income before provision for income tax	34,133	30,270	26,377
Provision for income tax	3,404	807	1,169
Net income	$ 30,729	$ 29,463	$ 25,208
Basic net income per share	$ 0.61	$ 0.59	$ 0.49
Diluted net income per share	$ 0.58	$ 0.56	$ 0.48
Weighted average shares used in computing:
Basic net income per share	50,235	49,797	51,277
Diluted net income per share	52,566	52,173	52,684

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 30,729	$ 29,463	$ 25,208
Other comprehensive loss, net of income tax:
Foreign currency translation	(1,666)	(1,194)	(912)
Unrealized loss on available-for-sale investment in common stock of third party	(1,924)
Total other comprehensive loss	(3,590)	(1,194)	(912)
Total comprehensive income	$ 27,139	$ 28,269	$ 24,296

Consolidated Statements Of Stoc

Consolidated Statements Of Stockholders’ Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 52	$ 278,327	$ 4,176	$ (135,960)	$ 146,595
Balance, shares at Dec. 31, 2013	52,372,000
Net income				25,208	25,208
Other comprehensive loss related to foreign currency translation			(912)		(912)
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net	$ 2	5,212			5,214
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net, shares	1,399,000
Compensation related to stock-based awards		3,569			3,569
Repurchase of common stock	$ (4)			(24,396)	$ (24,400)
Repurchase of common stock, shares	(3,822,000)				(3,822,434)
Balance at Dec. 31, 2014	$ 50	287,108	3,264	(135,148)	$ 155,274
Balance, shares at Dec. 31, 2014	49,949,000
Net income				29,463	29,463
Other comprehensive loss related to foreign currency translation			(1,194)		(1,194)
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net	$ 2	4,390			4,392
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net, shares	1,111,000
Compensation related to stock-based awards		4,588			4,588
Repurchase of common stock	$ (2)			(12,809)	$ (12,811)
Repurchase of common stock, shares	(1,526,000)				(1,526,306)
Balance at Dec. 31, 2015	$ 50	296,086	2,070	(118,494)	$ 179,712
Balance, shares at Dec. 31, 2015	49,534,000
Net income				30,729	30,729
Other comprehensive loss related to foreign currency translation			(1,666)		(1,666)
Other comprehensive loss related to unrealized loss on available-for-sale investment in common stock of third party			(1,924)		(1,924)
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net	$ 1	1,857			1,858
Issuance of common stock from exercise of stock options, restricted stock units, and employee stock purchase plan, net, shares	1,703,000
Compensation related to stock-based awards		6,656			6,656
Balance at Dec. 31, 2016	$ 51	$ 304,599	$ (1,520)	$ (87,765)	$ 215,365
Balance, shares at Dec. 31, 2016	51,237,000

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities:
Net income	$ 30,729	$ 29,463	$ 25,208
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash expense related to stock-based compensation	6,433	4,441	3,465
Provision for doubtful accounts		541
Provision for expiring inventory	34	0	2,099
Depreciation and amortization	985	931	852
Loss on disposal of fixed assets	1	3	26
Deferred income taxes	292	12	(321)
Unrealized foreign exchange loss	190
Changes in operating assets and liabilities:
Accounts receivable, net	(2,405)	306	(3,276)
Inventories	(3,001)	1,432	5,382
Prepaid expenses and other assets	273	(1,020)	(277)
Restricted cash in escrow for SEC settlement (Note 15)		(12,826)
Accounts payable	(3,123)	(2,295)	(5,485)
Accrued and other current liabilities	4,286	11,997	(414)
Deferred revenue	(173)	(422)	340
Other long-term liabilities	6	(56)	10
Net cash provided by operating activities	34,527	32,507	27,609
Investing activities:
Investment in available-for-sale security of third party (Note 5)	(2,718)
Loans to third party (Note 6)		(7,250)	(4,751)
Proceeds from the sale of short-term investments		75
Purchases of property and equipment	(648)	(1,835)	(1,452)
Net cash used in investing activities	(3,366)	(9,010)	(6,203)
Financing activities:
Repurchase of common stock including commissions		(12,811)	(24,400)
Repayment of credit facilities			(1,620)
Proceeds related to issuances of common stock, net	1,858	4,392	5,214
Net cash provided by (used in) financing activities	1,858	(8,419)	(20,806)
Effect of exchange rate changes on cash and cash equivalents	(27)	97	(175)
Net increase in cash and cash equivalents	32,992	15,175	425
Cash and cash equivalents, beginning of period	101,403	86,228	85,803
Cash and cash equivalents, end of period	134,395	101,403	86,228
Supplemental disclosure of cash flow information:
Net income taxes paid related to foreign operations	1,794	$ 1,509	944
Interest and unused line fees paid related to borrowings			$ 48
Release of restricted cash in escrow for SEC settlement	$ 12,826

The Company And Summary Of Sign

The Company And Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
The Company And Summary Of Significant Accounting Policies [Abstract]
The Company And Summary Of Significant Accounting Policies	Note 1 — The Company and Summary of Significant Accounting Policies Description of Business SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”), incorporated in 1990, is a United States (“U.S.”)-headquartered, China-focused, specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company’s lead product, ZADAXIN ® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately 7 partnered and in-licensed products in China. SciClone is also pursuing the registration of several other therapeutic products in China. Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated from the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make informed estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Cash Equivalents and Investments Cash equivalents consist of highly liquid investments with original maturities of three months or less on the date of purchase. The Company records its investments at fair value, as determined by available information on the consolidated balance sheet date. The Company’s cash investment portfolio as of December 31, 2016 consisted of money market funds that were included in cash and cash equivalents. As of December 31, 2016, the Company’s investment portfolio also included an available-for-sale investment in the common stock of a third party (No te 5) categorized within Level 2 of the fair value hierarchy. The Company records unrealized gains or losses on available-for-sale equity investments in other comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale equity investments are included in earnings. Available-for-sale investments are evaluated for impairment each reporting period. An investment is considered impaired if the fair value of the investment is less than its cost. If, after consideration of all available evidence to evaluate the realizable value of its investment, impairment is determined to be other-than-temporary, then an impairment loss is recognized in the consolidated statement of operations. No such losses were recorded in the periods presented. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. The three levels of input are: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Where quoted prices are available in an active market, the Company determines fair value based on quoted market prices, and classifies these values in level 1 of the valuation hierarchy. If quoted market prices are not available, fair values are based on observable inputs such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities and are classified in level 2 of the valuation hierarchy. When quoted prices and observable inputs are unavailable, fair values are based on cash flow models and are classified in level 3 of the valuation hierarchy. The cash flow models use inputs specific to the asset or liabilities including estimates for interest rates and discount rates including yields of comparable traded instruments adjusted for illiquidity and other risk factors, amount of cash flows and expected holding periods of the assets and liabilities. These inputs reflect the Company’s assumptions about the assumptions market participants would use in pricing the assets and liabilities including assumptions about risk developed based on the best information available in the circumstances. The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment, and may materially affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. The Company’s policy is to recognize transfers between levels as of the date of the event or change in circumstance that caused the transfer. Other financial instruments, including accrued short-term liabilities, are carried at cost, which the Company believes approximates fair value because of the short-term maturity of these instruments. Concentration of Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, accounts receivable, and loans receivable. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents, and by customers and partners in the event of default by the customer or partner to pay the amounts due to the Company on receivables and loans receivables, respectively, to the extent of the amounts recorded on the consolidated balance sheet. Most of the Company’s cash and cash equivalents are held by financial institutions that the Company believes are of high credit quality. At times, deposits may exceed government insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company is exposed to risk of its investment in the common stock of a third party losing market value. In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN, the Company manufactures its product using its U.S. and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Holding Lingyun Biopharmaceutical (Shanghai) Co. Limited (“Sinopharm”). Sinopharm acts as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for replacement of product in the events of damaged product or quality control issues. As the Company bears risk of loss until delivery has occurred, revenue is not recognized until the shipment reaches its destination. After the Company’s sale of ZADAXIN to the importer, Sinopharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier (“Tier 2”) distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier (“Tier 3”) local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors. Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers. Sinopharm contributed 93% , 97% and 94% of the Company’s total net revenue for the years ended December 31, 2016, 2015 and 2014, respectively, which revenues related to the Company’s China segment. There were no other customers that exceeded 10% of the Company’s total net revenue in those years. Total ZADAXIN product sales were $150.1 million or 96% , $146.1 million or 95% , and $126.1 million or 96% , of total product sales for the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, approximately $ 39.5 million, or 95 %, of the Company's gross accounts receivable was attributable to one customer, Sinopharm, in China. The Company generally does not require collateral from its customers. The Company maintains reserves for potential credit losses and such actual losses may vary significantly from its estimates. The Company currently relies on two suppliers to provide key components to its ZADAXIN manufacturing supply. Although there are a limited number of manufacturers who would be able to meet the requirements to manufacture these components, the Company believes that other suppliers could provide similar components on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which would affect operating results adversely. Per the Company’s previous contractual arrangement with Sinopharm through December 31, 2015, and a renewed contractual arrangement with Sinopharm (the Company’s sole distributor for ZADAXIN in China) which took effect January 1, 2016, the Company’s sales of ZADAXIN to Sinopharm were denominated in U.S. dollars through June 30, 2016. However, the established importer price was adjusted quarterly based upon exchange rate fluctuations between the U.S. dollar and Chinese Yuan Renminbi (“RMB”) . Effective July 1, 2016, the Company’s sales of ZADAXIN to Sinopharm are and will be denominated in RMB. A significant portion of the Company’s other revenues and expenses are also denominated in RMB and a significant portion of the Company’s assets and liabilities are denominated in RMB and all are exposed to foreign exchange risk. In the recent year and months, the RMB has experienced devaluation. Such devaluation negatively affects the U.S. dollar value of revenues while it positively affects the U.S. dollar value of China operating expenses. RMB is not freely convertible into foreign currencies. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions at the exchange rates quoted by the People’s Bank of China. Remittances in currencies other than RMB by the Company in China require certain supporting documentation in order to process the remittance. Accounts Receivable Reserve The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are charged off at the point when they are considered uncollectible. As of December 31, 2016, the Company determined no bad debt reserve was necessary. As of December 31, 2015, the Company had a receivable reserve of $0.5 million related to accounts receivable from one customer that was more than one year past due. During 2014, the Company’s subsidiary, SciClone Pharmaceuticals International China Holding Ltd (“SPIL China”) executed an agreement with this customer providing for settlement of the receivable balance, which at the time was $3.0 million. The terms of the settlement agreement resulted in the write-off of $1.1 million in previously fully reserved accounts receivable with an equivalent charge-off of the allowance for bad debt, which had no impact on net income in 2014. Of the remaining $1.9 million receivable balance, $0.5 million, $0.4 million and $1.0 million were collected in 2016, 2015 and 2014, respectively, per the terms of the settlement agreement, and these gains on recovery were recorded as reductions to general and administrative expense for those years. The Company recognized $0.5 million of bad debt expense in general and administrative expense during the first quarter of 2015 related to past due receivables from another customer due to uncertainty regarding the collectability of the customer’s outstanding receivable balance. The Company wrote-off the $0.5 million of past due accounts receivable from this customer during the fourth quarter of 2015 as uncollectible. Inventories Inventories consist of raw materials, work in progress and finished goods products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the impairment is first indicated. During the years ended December 31, 2016, 2015, and 2014, the Company recorded inventory write-downs of $34,000 , $0 , and $2.1 million, respectively, principally related to carrying value reductions for excess Aggrastat ® product in the 2014 period. As of December 31, 2016, there was zero remaining Aggrastat product in inventory following a discontinuation of the product. (Refer to Note 14 for further information regarding the discontinuation of Aggrastat.) Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recorded over the estimated useful lives of the respective assets on the straight-line basis. Office furniture and fixtures are generally amortized over five years, office equipment and computer software are generally amortized over three years, and the Company’s vehicle is being amortized over four years. Leasehold improvements are amortized over the shorter of the estimated useful life or lease term on the straight-line basis. The Company’s policy is to identify and record impairment losses, if necessary, on property and equipment when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. Goodwill The Company accounted for the acquisition of NovaMed Pharmaceuticals, Inc. (“NovaMed”) in 2011 under the acquisition method of accounting in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 805, Business Combinations . Under the acquisition method of accounting, the total acquisition-date fair value of the assets and liabilities are recognized as of the closing date. The excess of the fair value of the total consideration transferred over the acquisition-date fair value of net tangible and intangible assets and liabilities assumed was allocated to goodwill. Goodwill is tested for impairment at least annually, or whenever events or circumstances occur that indicate impairment might have occurred in accordance with ASC Topic 350, Intangibles — Goodwill and Other . Goodwill relates to the Company’s China segment which focuses on the Company’s primary pharmaceutical distribution market , consisting of the NovaMed business and the legacy China business, which represent a single reporting unit. As of December 31, 2016, 2015 and 2014, the Company tested its goodwill for impairment by quantitatively comparing the fair value of the reporting unit to its carrying amount - step one of the two-step impairment test. The Company bypassed the optional qualitative screening test in proceeding directly to step one of the two-step impairment test. The Company estimates the fair value of the China reporting unit using a discounted cash flow model. This valuation approach considers a number of factors that include, but are not limited to, expected future cash flows, growth rates, discount rates, and requires the Company to make certain assumptions and estimates regarding industry economic factors and future profitability of the Company’s business. If the Company determines that the carrying value of its reporting unit exceeds its fair value, the Company would then calculate the implied fair value of the reporting unit goodwill as compared to its carrying value to determine the appropriate impairment charge. After completing the Company’s impairment review for the reporting unit as of December 31, 2016, 2015, and 2014, the Company concluded that goodwill was not impaired in any of these years. Loans Receivable Loans receivable are due from a single third party (see Note 6). Loans are initially recorded, and continue to be carried, at unpaid principal balances under “other assets” on the consolidated balance sheet. Carried balances are subsequently adjusted for payments of principal or adjustments to the allowance for loan losses to account for any impairment. Interest income is recognized over the term of the loans and is calculated using the simple-interest method, as the loans do not have associated premium or discount. If the loans were to experience impairment, interest income would not be recognized unless the likelihood of further loss was remote. Although the measurement basis is unpaid principal (as adjusted for subsequent payments or impairment), not fair value, the loans receivable would qualify as Level 3 measurements under the fair value hierarchy (Note 2) due to the presence of significant unobservable inputs related to the counterparty, which is a private entity. Management considers impairment to exist when, based on current information or factors (such as payment history, value of collateral, and assessment of the counterparty’s current creditworthiness), it is probable that principal and interest payments will not be collected according to the contractual agreements. Management considers a loan payment delinquent when not received by the due date. As of December 31, 2016 and 2015, management concluded the loans receivable were not impaired, and there was no allowance for loan losses. Accrued Expenses The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to them. Examples of estimated accrued expenses include fees paid to contract research organizations and investigative sites in connection with clinical trials, fees paid to contract manufacturers in connection with the production of materials, and professional services. The Company periodically confirms the accuracy of its estimates with selected service providers and makes adjustments, if necessary, in the periods identified. Expenses related to clinical trials charged to research and development expense generally are accrued based on estimates of work performed or the level of patient enrollment and activities according to the protocols and agreements. The Company makes adjustments, if necessary, in the periods identified to reflect actual levels of work performed, and such adjustments have historically not been material. T he financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under certain contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses to the actual services received and efforts expended. The Company monitors planned protocols, work performed, patient enrollment levels and related activities to the extent possible and adjusts estimates accordingly. The Company records as liabilities estimated amounts for litigation, claims or other legal actions that are probable and can be reasonably estimated. The likelihood of a material change in these estimated reserves is dependent on the possible outcome of settlement negotiations, regulatory or judicial review and the development of facts and circumstances in extended litigation which could change claims or assessments when both the amount and range of loss on some outstanding litigation is uncertain. The Company discloses in the footnotes to the financial statements when it is unable to make a reasonable estimate of a material liability that is reasonably possible to result from unfavorable outcomes. As events occur, the Company assesses the potential liability related to any pending litigation, claims or other legal actions and adjusts its estimates accordingly. Such adjustments could materially impact its financial statements. Foreign Currency Translation The Company translates the assets and liabilities of its foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using average rates of exchange in effect during the period. Goodwill, and certain other balances, are generally recorded in the local currency which is the functional currency of the Company’s subsidiaries located in China. As a result, the carrying value of goodwill and certain other balances may fluctuate with the value of the RMB as compared to the U.S. dollar. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of stockholders' equity. The Company records foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction losses were $2.2 million and $0.4 million for the year ended December 31, 2016 and 2015, respectively. For the year ended December 31, 2014 foreign currency transaction gains and losses were not significant. Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured. Product Revenue. The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to Sinopharm are recognized upon arrival of a shipment to its destination, which marks the point when title and risk of loss to product are transferred. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors. Effective January 1, 2016, the Company’s new contractual arrangement with its China importer and distributor for ZADAXIN, Sinopharm, is resulting in the later recognition (relative to practices prevailing under the old contractual arrangement through December 31, 2015) of a portion of the Company’s revenue due from Sinopharm related to situations where the provincial tender price is greater relative to a reference (baseline) tender price. The tender price is the ultimate retail end price approved by provincial authorities. There is a price mechanism in the new contractual arrangement whereby Sinopharm is invoiced at a lower base price relative to that prevailing in the previous agreement. The lower base price (reduced by estimated price compensation payable to Sinopharm for situations where the provincial tender price is lower than the reference (baseline) tender price) is recorded as revenue at the time the sale is completed upon arrival at destination. To date, there are no situations where a provincial tender price is less than the reference (baseline) tender price. Sinopharm is invoiced for the portion of the price that results from situations where the provincial tender price is greater than the reference (baseline) tender price at a later time, and such amount is recognized as revenue after the amount has been agreed to with them. It is expected that the price compensation due to the Company related to sales in a quarter under the price adjustment mechanism for provinces with tender prices above the reference (baseline) tender price will continue to be recognized on a rolling one-to-two quarter delayed basis relative to the originating sales quarter. Promotion Services Revenue. The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in a promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. Revenue Reserve . The Company generally maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which are based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired or are deemed to be damaged or defective when delivered upon arrival at destination. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of December 31, 2016 and 2015, the Company’s revenue reserves were $0.3 million and $0.1 million, respectively, on its consolidated balance sheets. The Company evaluates the need for a returns reserve quarterly and adjusts it when events indicate that a change in estimate is appropriate. Changes in estimates could materially affect the Company’s results of operations or financial position. It is possible that the Company may need to adjust its estimates in future periods. Sales Tax and Surcharge Expense Sales taxes and surcharge costs are expensed as incurred and are included in sales and marketing expense. The Company is generally subject to a 5 - 6.42 % business tax and surcharge for services provided related to marketing products under the relevant taxation laws in China. Sales tax and surcharge costs amounted to approximately $3.8 million, $3.4 million, and $ 2.5 million for the years ended December 31, 2016, 2015, and 2014, respectively. Research and Development Expenses Research and development costs are expensed as incurred. These costs include salaries and other personnel-related expenses, including associated stock-based compensation, facility-related expenses, depreciation of facilities and equipment, upfront and milestone payments under in-licensing agreements with certain business partners and other license-related fees, and services performed by clinical research organizations and research institutions and other outside service providers. Shipping and Handling Costs Shipping and handling costs incurred for inventory purchases and product shipments are included in cost of product sales for all periods presented. Advertising Expenses Advertising costs are expensed as incurred and are included in sales and marketing expenses for all periods presented. Advertising expenses for the years ended December 31, 2016, 2015, and 2014, were $1.7 million, $ 4.1 million, and $2.6 million, respectively. Legal Costs Legal costs related to loss contingencies are expensed to general and administ rative expense as incurred. Stock-Based Compensation The Company records stock-based compensation costs relating to share-based payment transactions, including stock options, restricted stock units (“RSUs”), performance restricted stock units (“PSUs”) and the employee stock purchase plan (“ESPP”). Stock-based compensation expense for stock options and the employee stock purchase plan is estimated at the date of grant based on the fair value of the award using the Black-Scholes option-pricing model. Stock-based compensation expense for RSUs and PSUs are estimated at the date of grant based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. Stock-based compensation expense values for stock options, RSUs and the ESPP are recognized as expense on a straight-line basis over the requisite service period, net of estimated forfeitures. The stock-based compensation costs that are ultimately expected to vest are recognized as expense ratably (as the awards vest) over the requisite service period, which is generally one or four years for stock options and RSUs and three months for the ESPP. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The total expense recognized over the vesting period will only be for those awards that ultimately vest. The Company recognizes expense related to the PSUs and performance stock options over the implicit service period if it is probable that the performance goals will be achieved. If it is subsequently determined that the performance goals are not probable of achievement, the expense related to the PSUs or performance stock options is reversed. Income Taxes Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more-likely-than-not that the deferred tax assets will not be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made. The Company records liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period. The Company’s policy is to recognize interest and penalties related to the liabilities for uncertain tax positions as a component of income tax expense. The amount of accrued interest related to tax positions taken on the Company’s tax returns and included in accrued and other current liabilities was $1.7 million as of December 31, 2016 and 2015. The amount of interest recognized as tax expense related to uncertain tax positions in the consolidated statements of income was $0.1 million, $0.2 million and $0.3 million for the years ended December 31, 2016, 2015 and 2014, respectively. Net Income

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 2 — Fair Value Measurements The following tables represent the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis (in thousands):     Fair Value Measurements as of December 31, 2016 Using   Quoted Prices in Significant  Active Markets Other Significant  for Observable Unobservable Balance  Identical Assets Inputs Inputs as of  Description (Level 1) (Level 2) (Level 3) December 31, 2016  Money market funds $ 19,701 $ — $ — $ 19,701  Common stock investment in third party (Note 5) — 794 — 794  Total $ 19,701 $ 794 $ — $ 20,495       Fair Value Measurements as of December 31, 2015 Using   Quoted Prices in Significant  Active Markets Other Significant  for Observable Unobservable Balance  Identical Assets Inputs Inputs as of  Description (Level 1) (Level 2) (Level 3) December 31, 2015  Money market funds $ 19,678 $ — $ — $ 19,678  Total $ 19,678 $ — $ — $ 19,678  

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Inventories	Note 3 — Inventories Inventories consisted of the following (in thousands):    December 31,  2016 2015  Raw materials $ 5,304 $ 3,871  Work in progress 498 535  Finished goods 10,785 6,570  Total $ 16,587 $ 10,976  As of December 31, 2016 and 2015, the Company had $ 4.6 million and $3.3 million, respectively, in inventory held at distributors related to non–ZADAXIN products.

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2016
Property And Equipment [Abstract]
Property And Equipment	Note 4 — Property and Equipment Property and equipment consisted of the following (in thousands) :    December 31,  2016 2015  Construction in process $ 14 $ 18  Office equipment 3,363 3,172  Leasehold improvements 1,513 1,281  Office furniture and fixtures 1,320 1,377  Software 936 897  Vehicle 81 67  Gross property and equipment 7,227 6,812  Less accumulated depreciation (5,225) (4,161)  Net property and equipment $ 2,002 $ 2,651  Depreciation expense was $1.0 million, $0.9 million and $0.9 million for each of the years ended December 31, 2016, 2015, and 2014, respectively.

Investments In Third Party

Investments In Third Party	12 Months Ended
	Dec. 31, 2016
Investments In Third Party [Abstract]
Investments In Third Party	Note 5 — Investment in Third Party On September 9, 2016, the Company and Soligenix, Inc., a publicly-traded entity, entered into an exclusive license agreement (the “License Agreement”), including a common stock purchase agreement, pursuant to which Soligenix granted rights to the Company to develop, promote, market, distribute and sell an oral mucositis-targeted drug candidate (“SGX942”) in the People’s Republic of China, Hong Kong, Macau, Taiwan, South Korea and Vietnam (the “Territory”). Under the terms of the License Agreement, the Company will be responsible for all aspects of development, product registration, and commercialization in the Territory, having access to data generated by Soligenix. In exchange for exclusive rights, beyond an upfront payment, the Company will pay to Soligenix royalties on net sales, and Soligenix will supply commercial drug product to the Company on a cost-plus basis, while maintaining worldwide manufacturing rights. This exclusive agreement builds on an existing collaboration between the two companies established in 2013, in which the Company provided its complete oral mucositis clinical and regulatory data library to Soligenix in exchange for certain, previously undisclosed, commercialization rights to the oral mucositis drug candidate in the Greater China market. As the Company obtained rights for Greater China (mainland China, Hong Kong, and Macau) in the earlier 2013 exchange, the September 2016 agreement in substance represented the acquisition of additional rights for Taiwan, South Korea, and Vietnam. As part of the License Agreement, the Company entered into a common stock purchase agreement with Soligenix pursuant to which the Company bought 3,529,412 shares of Soligenix common stock. These common shares are unregistered but the Company has demand registration rights and can compel a registration of the securities in a reasonably short time in the event the Company plans to sell the shares. The total cash consideration of $3,000,000 paid to Soligenix at the time of the transaction reflected the purchase price of the common stock and the consideration for expanded territorial rights in South Korea, Taiwan and Vietnam. As of the transaction date, the common stock was recorded at an initial fair value of $2.7 million representing publicly quoted closing share prices from the OTCQB, the over-the-counter market on which Soligenix’s securities were listed at the time. The residual cash consideration of $0.3 million related to the expanded territorial rights was recorded as research and development expense in the third quarter of fiscal 2016. The Company is holding the Soligenix shares in the context of a business relationship, and as such has classified them as available-for-sale. The common stock investment is adjusted to fair value at each reporting date with unrealized gains (losses) reported as a component of other comprehensive income (loss). In October 2016, in connection with an up-listing of its stock from the OTCQB market to the NASDAQ Common Market, Soligenix declared a 1 for 10 reverse stock split, converting the Company’s ownership in Soligenix from 3,529,412 shares to 352,94 2 shares. As of December 31, 2016, the fair value of the Soligenix common stock investment was $0.8 million and the unrealized holding loss on the investment was $1.9 million, which was recorded as a component of other comprehensive loss (net of tax, which is zero as the entity holding the security is in a zero-tax jurisdiction) . The Company determined that the write-down of fair value was not other-than-temporary after considering the volatility of the common stock and other investee-specific facts and circumstances.

Loans Receivable

Loans Receivable	12 Months Ended
	Dec. 31, 2016
Loans Receivable [Abstract]
Loans Receivable	Note 6 — Loans Receivable As part of the Company’s May 2013 license and supply agreement with Zensun (Shanghai) Science & Technology Co. Ltd (“Zensun”), the Company previously agreed to loan up to $12 million to Zensun. The entry into the license and supply agreement in the second quarter of 2013, pursuant to which the Company licensed the exclusive rights to promote, market, distribute, and sell Neucardin TM , a chronic heart failure product under development by Zensun (such rights licensed for the People’s Republic of China, Hong Kong and Macao) is more fully described in Note 13. Pursuant to its agreement to loan funds, the Company loaned $12 million to Zensun. The extension of credit and funding to Zensun was accomplished through two of the Company's subsidiaries, SPIL China, and SciClone Pharmaceuticals (China) Ltd. (“SciClone China”). With respect to lender SciClone China, Zensun can make RMB-denominated borrowings for up to RMB 1,550,000 using an entrustment mechanism with a bank as an intermediary. In the third quarter of 2014, SciClone China entered into an entrusted loan agreement for RMB 1,550,000 (approximately U.S. $223,000 as of December 31, 2016) with Zensun, using a major Chinese bank as the lending agent. SciClone China is the principal and ultimately bears the credit risk, not the bank. The loan bears interest at a fixed rate of 7.5% per annum and Zensun is subject to obligations of the borrower as specified in the loan agreements. The loan term is sixty-six months. All outstanding principal and interest balances must be repaid by the maturity date, with prepayments permitted without penalty upon prior notice. With respect to lender SPIL China, Zensun could request U.S.-dollar denominated borrowings up to $11.75 million. As of December 31, 2016, borrowings totaling $11.75 million had been requested by Zensun and paid by SPIL China with $4.5 million lent in the second half of 2014 and $7.25 million lent in the second quarter of 2015. These borrowings bear interest at a fixed rate of 7.5% per annum payable annually in arrears at each interest payment date as defined in the overall loan agreement. These borrowings were originally scheduled to mature on September 26, 2017 , with an option (granted at loan origination) electable by Zensun to extend for two additional years provided certain conditions are met. As of December 31, 2016, the borrower had notified the Company of its intent to exercise its option to extend the borrowings for two additional years, or to September 26, 2019 . All outstanding balances must be repaid by the maturity date, with prepayments permitted without penalty upon prior notice. The proceeds of the separate but related loans are to be used for working capital and general corporate purposes by Zensun. To secure the loans, Zensun pledged its entire equity interest in its subsidiary, Shanghai Dongxin Biochemical Technology Co. Ltd. (whose assets include real property) to SPIL China. Management, on the basis of (i) a creditworthiness evaluation using recent Zensun financial information, (ii) consideration of evidence of the market value of the pledged security indicating such market value exceeded the outstanding loan principal, and (iii) consideration of Zensun’s compliance with the terms of the loans and timely payments of interest, concluded there were no indications of loan impairment at December 31, 2016. Accordingly, there is no allowance for losses. The two loans are included in “other assets” on the Company’s consolidated balance sheet as of December 31, 2016 and 2015. Interest income on the loans amounted to $0.9 million, $0.8 million and $0.1 million for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in interest and investment income in the consolidated statements of income. The Company estimates the fair value of the loans receivable approximates $12.4 million as of December 31, 2016, based upon prevailing market rates of interest as published by major Chinese banks.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill [Abstract]
Goodwill	Note 7 — Goodwill The following table represents the changes in goodwill for the years ended December 31, 2016, 2015 and 2014 ( in thousands ):    Balance as of January 1, 2014 $ 35,357  Translation adjustments (836)  Balance as of December 31, 2014 $ 34,521  Translation adjustments (1,542)  Balance as of December 31, 2015 $ 32,979  Translation adjustments (2,141)  Balance as of December 31, 2016 $ 30,838 

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 8 — Accrued Liabilities The following is a summary of accrued liabilities (in thousands) :    December 31,   2016 2015  Accrued SEC settlement loss (Note 15) $ — $ 12,826  Accrued sales and marketing expenses 8,623 8,511  Accrued taxes, tax reserves and interest 5,335 4,323  Accrued compensation and benefits 5,140 4,341  Accrued professional fees 1,298 1,130  Accrued manufacturing costs 715 444  Other 1,685 576  Total $ 22,796 $ 32,151  

Commitments

Commitments	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies [Abstract]
Commitments	Note 9 — Commitments Purchase Obligations Under agreements with certain of the Company’s pharmaceutical partners, the Company is committed to certain annual minimum product purchases where the contract is subject to termination if the annual minimum order is not met. As of December 31, 2016, the Company did not have any material unmet purchase obligations. Leases In May 2007, the Company entered into a non-cancelable operating lease agreement for its corporate headquarters ("the Lease”) effective from July 1, 2007 through June 30, 2014. In September 2008, the Company entered into an amendment to the Lease for additional office space (“the Amendment”) that expired on June 30, 2014. Both the Lease and Amendment contained rent escalations of approximately 4 % and 6 % per year, respectively. In December 2013, the Company entered into a second amendment to the Lease extending the term of the lease for an additional four years through June 30, 2018, with an option to renew for an additional five year period. Beginning on July 1, 2014, the second amendment reduced the amount of leased office space from approximately 21,517 square feet leased to approximately 11,886 square feet. It also reduced the monthly base rent of $ 120,824 to $51,704 in the first year, with rent escalations of approximately 3% per year. In addition, the Company received a rent abatement for the first four months of the extended lease term. The Company is recognizing the rental expense on a straight-line basis over the lease term. Under the terms of the Lease and the Amendment, the Company was provided allowances in the amounts of approximately $ 0.2 million and $ 0.5 million, respectively, towards the cost of its leasehold improvements and as an incentive to rent, respectively. The Company has recorded these allowances as deferred rent which is being amortized over the lease term as a reduction of rent expense. The Lease requires the Company to pay insurance and taxes and its pro-rata share of operating expenses. In June 2014, the Company entered into a non-cancelable operating lease agreement for its primary office space in China (“the China Lease”) for a fixed lease term from October 15, 2014 through April 14, 2018, with options to renew for an additional two years. The Company is recognizing the rental expense on a straight-line basis over the lease term. The lease requires the Company to pay insurance and its pro-rata share of operating expenses. The Company also leases other office facilities and equipment outside the U.S. under non-cancelable operating lease agreements. Through May 2014, the Company also subleased certain office facilities to a third party. Rent expense for the years ended December 31, 2016, 2015, and 2014, was $2.1 million, $2.1 million, and $ 2.2 million, respectively, net of sublease income. Future minimum lease payments under non-cancelable facility and equipment operating lease agreements as of December 31, 2016, were as follows (in thousands) :    Minimum Lease  Year ended: Payments  2017 $ 2,311  2018 1,062  2019 267  2020 —  2021 —  $ 3,640  

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	Note 10 — Income Taxes The Company recorded income tax provisions of $3.4 million, $0.8 million, and $1.2 million for the years ended December 31, 2016, 2015, and 2014, respectively, related to its operations in China. Tax expense increased $2.6 million for the year ended December 31, 2016, compared to 2015, related to $1.3 million of additional tax expense representing the correction of an error related to a previously unrecognized liability for uncertain tax positions in China (refer also to Note 1, “ Error Correction ”) and due to higher sales and related marketing activities in the Company’s China business for the year ended December 31, 2016 . Tax expense decreased for the year ended December 31, 2015, compared to 2014, mainly related to a reduction in the Company’s liabilities (and associated accrued interest) for uncertain tax positions in China due to certain tax years becoming closed to assessment due to the expiration of the statute of limitations as well as a result of lower taxable income related to restructuring the Company’s China operations. The Company’s statutory tax rate in China was 25 % in 2016, 2015 and 2014. The Company has not recorded any significant U.S. federal or state income taxes for the years ended December 31, 2016, 2015, and 2014 . The Company has concluded that its offshore undistributed accumulated earnings as of December 31, 2016 of $211 million, exclusive of the dividend repatriations which were entirely satisfied out of fiscal 2016 and 2015 earnings and profits, respectively, as further explained below, continues to be indefinitely reinvested outside of the U.S., and has therefore provided no taxes thereon. Upon any distribution of accumulated undistributed earnings, the Company may be subject to U.S. federal and state income taxes, although determining the amount is not practicable as it is dependent on a variety of factors, including, but not limited to, the amounts of U.S. tax loss carryforwards and tax credit carryforwards available at the time of the repatriation. During 2016, $10 million in dividend distributions were made to the parent company to address the parent company’s liquidity needs from fiscal 2016 earnings and profits of its foreign subsidiaries which were not part of the cumulative pool of undistributed earnings of foreign subsidiaries as of December 31, 2015. The repatriation did not result in any additional U.S. federal or state tax liability for 2016 as tax-deductible corporate expenses incurred and consumption of available accumulated net operating loss, fully offset the amount of the taxable income represented by the dividend distributions. Accordingly, related tax provided were zero. During the fourth quarter of fiscal 2015, the Company also repatriated a special dividend distribution of $12.8 million related to the SEC settlement expense (as further described in Note 15) from fiscal 2015 earnings and profits of its foreign subsidiaries, which were not part of the cumulative pool of undistributed earnings of foreign subsidiaries as of December 31, 2014. The Company recorded U.S. federal income taxes for this income as a component of the 2015 income tax provision; however, the net effect of the special dividend distribution on the 2015 income tax provision was zero as the incremental taxable income (as well as the nondeductible applicable SEC settlement expenses) were fully offset by tax-deductible corporate expenses. Based on the Company’s current liquid resources and future operating plan, it does not need to repatriate undistributed earnings held by foreign subsidiaries accumulated through December 31, 2016. However, to meet future operating needs, the Company may repatriate a portion of future annual foreign earnings in a forthcoming annual period. The Company plans to accrue for U.S. income taxes on future foreign earnings that it anticipates repatriating from its foreign subsidiaries. T he Company has significant on going corporate expenses and accumulated net operating loss and tax credit carryforwards available to offset any tax liability on a dividend distribution from its foreign subsidiaries. The domestic and foreign components of income (loss) before provision for tax for the years ended December 31 are as follows (in thousands) :   2016 2015 2014  Domestic $ (8,363) $ (17,017) $ (8,496)  Foreign 42,496 47,287 34,873  Pre-tax income $ 34,133 $ 30,270 $ 26,377  A reconciliation of tax at the statutory federal income tax rate of 34% to the actual tax provision for the years ended December 31 is as follows (in thousands) :    2016 2015 2014  Tax at federal statutory rate $ 11,605 $ 10,382 $ 8,968  Foreign income taxed at different rates (11,712) (15,210) (10,788)  Federal tax effect of dividend from foreign subsidiary 2,999 4,317 —  Effect of uncertain tax positions 667 (126) 127  Change in valuation allowance (199) 1,092 2,672  Stock-based compensation (604) (86) 2  Nondeductible expenses 247 189 189  Other 401 249 (1)  Provision for income tax $ 3,404 $ 807 $ 1,169   The provision for income taxes for the years ended December 31 consisted of the following ( in thousands ):    2016 2015 2014  Federal $ — $ — $ —  State 1 1 1  Foreign 3,103 793 1,489  Total current 3,104 794 1,490  Federal — — —  State — — —  Foreign 300 13 (321)  Total deferred 300 13 (321)  Provision for income tax $ 3,404 $ 807 $ 1,169  Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows ( in thousands ):     2016 2015  Deferred tax assets:  Net operating loss carryforwards $ 36,938 $ 38,679  Research and development credit carryforwards 10,719 10,650  Intangibles 530 382  Other 2,543 2,692  Gross deferred tax assets 50,730 52,403  Valuation allowance (50,730) (52,104)  Total deferred tax assets — 299  Deferred tax liabilities:  Other — —  Total deferred tax liabilities — —  Net deferred tax assets $ — $ 299  Realization of deferred tax assets is dependent upon the Company generating future taxable income, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance with the exception of a net operating loss carryforward in a foreign jurisdiction as of the end of 2015 which was used to offset taxable income in 2016. The valuation allowance (decreased) increased by approximately ($1.4) million, $1.4 million, and $ 3.4 million, in the years ended December 31, 2016, 2015, and 2014, respectively. Approximately $4.4 million of the valuation allowance relates to benefits associated with stock option deductions that, when recognized, will be credited directly to stockholders' equity. As of December 31, 2016, the Company had U.S. federal net operating loss carryforwards of approximately $ 112.9 million that expire in the years 2020 through 2035 , and U.S. federal research and development, orphan drug and investment tax credit carryforwards of approximately $ 12.3 million that expire in the years 2018 through 2036 . As of December 31, 2016, the Company had approximately RMB 40.8 million in net operating loss carryforwards related to its NovaMed Pharmaceuticals (Shanghai) Co. Ltd. (“ NovaMed Shanghai ”) subsidiary that expire in the years 2019 through 2021 . As of December 31, 2016, the Company had state net operating loss carryforwards of approximately $ 25.9 million that expire in the years 2017 through 2030 , if not utilized, and state research and development tax credit carryforwards of approximately $ 2.2 million that do not expire. Utilization of the Company’s net operating loss and credit carryforwards may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the net operating loss and credit carryforwards before utilization. As of December 31, 2016, the unrecognized tax benefit was $ 5.8 million, of which $ 2.2 million, if recognized would affect the effective tax rate, and $ 3.6 million, if recognized, would be offset by a change in the valuation allowance. Accrued interest associated with the liability for unrecognized tax benefits was $ 1.7 million as of December 31, 2016. A reconciliation of the beginning and ending amount of unrecognized tax benefit for the years ended December 31 is as follows (in thousands):    2016 2015 2014  Balance beginning of period $ 5,470 $ 5,876 $ 6,138  Tax positions related to current year:  Additions for current year items 25 14 32  Additions for prior year items (see Note 1) 1,009 — —  Lapse of statute of limitations (604) (288) (206)  Changes for foreign currency translation (117) (132) (88)  Balance end of period $ 5,783 $ 5,470 $ 5,876   Tax years 1995-2016 remain open to examination by the major U.S. taxing jurisdictions to which the Company is subject. The Internal Revenue Service concluded its examinations of the Company’s 2011, 2009 and 2008 U.S. federal tax returns with no additional tax assessments or proposed adjustments relating to taxable income for any years. The Company’s China operations are generally subject to examination under China tax law for a period of five years and those five years remain open for examination. The outcome of income tax examinations is uncertain, and the amounts ultimately paid, if any, on resolution of any issues raised by the taxing authorities may differ materially from the amounts accrued for each year. The Company anticipates that its liability for unrecognized tax benefits will decrease over the next 12 months on account of expiries of statutes of limitations associated with certain tax jurisdictions, and that such decreases will favorably impact the effective tax rate.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 11 — Stockholders’ Equity Stock Award Plans The Company’s 2015 Equity Incentive Plan (the “2015 Plan”) became effective on June 11, 2015 and superseded the 2005 Equity Incentive Plan (the “2005 Plan”) and the 2004 Outside Directors Stock Option Plan (the “2004 Director Plan”), when those plans terminated upon the adoption of the 2015 Plan. The 2015 Plan authorizes the Company to issue up to 6,550,000 shares increased by not more than 3,000,000 additional shares that were subject to options and other awards outstanding under the 2005 Plan and 2004 Director Plan, to the extent that such awards expire or are forfeited for any reason after the effective date of the 2015 Plan. The 2015 Plan permits the grant of incentive stock options, nonstatutory stock options, RSUs, PSUs and other forms of equity compensation. Under the 2015 Plan, options are exercisable upon conditions determined by the Board of Directors and expire ten years from the date of grant. Options have exercise prices equal to the grant date fair market value of a share of Company common stock and vest over time, generally four years, or on achievement of certain performance conditions. See Stock-Based Compensation . The Company’s 2005 Plan had authorized up to 13,600,000 shares of common stock for issuance. The 2005 Plan permitted the grant of incentive stock options, nonstatutory stock options, RSUs, PSUs and other forms of equity compensation. Under the terms of the 2005 Plan, options are exercisable upon conditions determined by the Board of Directors and expire ten years from the date of grant. Options have exercise prices equal to the grant date fair market value of a share of Company common stock and vest over time, generally four years, or on achievement of certain performance conditions. See Stock-Based Compensation . As of December 31, 2016, no shares of common stock were available for future issuance of new awards under the 2005 Plan. Although the 2005 Plan has terminated, the outstanding stock options relating to it are fully valid and are governed by the terms of the 2005 Plan. The Company’s 2004 Director Plan authorized up to 1,765,000 shares of common stock for issuance. The 2004 Director Plan automatically granted nonqualified stock options to nonemployee directors on their appointment or first election to the Company’s Board of Directors (“Initial Grant”) and annually on their reelection to the Board of Directors at the Company’s Annual Meeting of Stockholders (“Annual Grant”). Under the 2004 Director Plan, options have exercise prices equal to the grant date fair market value of a share of Company common stock and expire ten years from the date of grant. Initial Grants became exercisable in three equal annual installments beginning on the first anniversary of the date of grant, and Annual Grants became exercisable in twelve equal monthly installments from the date of grant, subject in each case to the Director’s continuous service on the Company’s Board of Directors. As of December 31, 2016, no shares of common stock were available for future issuance of new awards under the 2004 Director Plan. Although the 2004 Director Plan has terminated, the outstanding stock options relating to it are fully valid and are governed by the terms of the 2004 Director Plan. Certain stock option awards are subject to accelerated vesting if there is a change in control. The Company issues new shares on exercise of stock options, for release of RSUs and PSUs and for issuance of stock under its ESPP. Stock-Based Compensation The following table summarizes the stock-based compensation expenses included in the Company’s consolidated statements of income ( in thousands ):     For the Year Ended December 31,   2016 2015 2014  Sales and marketing $ 984 $ 869 $ 1,031  Research and development 336 210 104  General and administrative 5,113 3,362 2,330  $ 6,433 $ 4,441 $ 3,465  Compensation cost capitalized in inventory was approximately $0.2 million, $0.1 million and $0.1 million, for each of the years ended December 31, 2016, 2015, and 2014, respectively. There has been no income tax benefit recognized in the income statement for share-based compensation arrangements as the arrangements relate to an entity with accumulated and ongoing tax net operating losses. Valuation Assumptions The fair value of awards granted under the Company’s stock option and ESPP plans is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the years ended December 31:    2016 2015 2014  Risk-free interest rate:  Time-based stock options 1.41 % 1.52 % 1.61 %  Performance-based stock options N/A N/A N/A  ESPP 0.36 0.07 0.04  Volatility factor of the market price of the Company's common stock:  Time-based stock options 48.53 % 52.08 % 57.96 %  Performance-based stock options N/A N/A N/A  ESPP 42.33 53.73 42.50  Weighted-average expected life (years):  Time-based stock options 5.24 5.30 5.00  Performance-based stock options N/A N/A N/A  ESPP 0.25 0.25 0.25  Dividend yield 0.00 % 0.00 % 0.00 %  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected dividend yield is based on the Company’s history and expectations of no dividend payouts. Expected volatility is based on the historical volatility of the Company’s stock. The expected term of options granted is derived from historical data on employee exercises and terminations. Stock Options The following table summarizes stock option activity as of December 31, 2016, 2015 and 2014, and changes during the years then ended are presented below (in thousands, except per share and term amounts) :    Options Outstanding   Weighted- Weighted-  Average Average  Number Exercise Remaining Aggregate  of Price Per Contractual Intrinsic  Shares Share Term (Years) Value  Balance as of January 1, 2014 6,095 $ 4.14 5.66 $ 7,199  Options forfeited (705) 5.10  Options granted 1,740 4.85  Options exercised (1,233) 4.43  Balance as of December 31, 2014 5,897 $ 4.17 6.08 $ 27,066  Options forfeited (262) 5.77  Options granted 1,414 8.83  Options exercised (1,022) 4.48  Balance as of December 31, 2015 6,027 $ 5.14 6.07 $ 24,462  Options forfeited (293) 8.20  Options granted 1,510 9.79  Options exercised (1,993) 3.66  Balance as of December 31, 2016 5,251 $ 6.87 6.87 $ 21,112  Vested and expected to vest after December 31, 2016 4,847 $ 6.71 6.71 $ 20,278  Exercisable as of December 31, 2016 2,840 $ 5.56 5.53 $ 15,112  The Company has granted certain performance-based options to purchase shares of the Company’s common stock at an exercise price equal to the closing price of a share of the Company’s common stock as of the grant date. The options will fully vest on meeting a performance goal within an established time frame. If the performance goal is met for the option within the established time frame, the option generally has a ten -year term measured from the date of grant. If the performance goal is not met within the established time frame, the option expires in its entirety. The Company recognizes expense related to a performance-based option over the period of time the Company determines that it is probable that the performance goal will be achieved. If it is subsequently determined that the performance goal is not probable of achievement, the expense related to the performance-based option is reversed. For the years ended December 31, 2016, 2015, and 2014, the Company recognized approximately $0 , $20,000 , and $ 0.1 million, respectively, of expense related to performance-based options. The weighted-average fair value of stock options granted for the years ended December 31, 2016, 2015, and 2014, was $4.33 , $4.18 , and $ 2.43 , respectively. The intrinsic value of options at time of exercise was $ 14 . 6 million, $4.7 million, and $ 2.4 million, for the years ended December 31, 2016, 2015, and 2014, respectively. The estimated fair value of options vested for the years ended December 31, 2016, 2015, and 2014 was $4.4 million, $3.9 million, and $ 3.2 million, respectively. As of December 31, 2016, unamortized compensation expense related to unvested options was approximately $ 6.6 million, net of forfeitures. The weighted average period over which compensation expense related to these options will be recognized is approximately 2.41 years. Cash received from stock option exercises was $5.6 million, $4.6 million, and $ 5.5 million for the years ended December 31, 2016, 2015, and 2014, respectively. In addition, the Company withheld 411,407 shares representing a value of $3.4 million to cover taxes and the exercise price in connection with the exercise of certain stock options. RSUs and PSUs The following table summarizes RSU and PSU activity as of December 31, 2016, 2015, and 2014 and changes during the years then ended are presented below (in thousands) :     RSUs and PSUs  Outstanding   Number Aggregate  of Intrinsic  Shares Value  Balance as of January 1, 2014 368 $ 1,857  Awarded 7  Vested/Released (212)  Forfeited (4)  Balance as of December 31, 2014 159 $ 1,393  Awarded 688  Vested/Released (105)  Forfeited —  Balance as of December 31, 2015 742 $ 6,822  Awarded 345  Vested/Released (151)  Forfeited (26)  Balance as of December 31, 2016 910 $ 9,825  Vested and expected to vest after December 31, 2016 775 $ 8,365  Exercisable as of December 31, 2016 (Vested and deferred) — —  The RSUs generally vest 25 % approximately one year after grant date with the remaining shares vesting approximately annually in equal installments over a one - to four -year period, depending on the terms of the grant. The PSUs will vest and be released on meeting specified performance goals (including revenue and product expansion targets) within an established time frame. If the performance goals are not met within the established time frame, the PSUs will expire. The Company recognizes expense related to the PSUs over the implicit service period if it is probable that the performance goals will be achieved. If it is subsequently determined that the performance goals are not probable of achievement, the expense related to the PSUs is reversed. For the years ended December 31, 2016, 2015 and 2014, the Company recorded approximately $0. 3 million, $0.1 million and $0 , respectively, of expense related to the PSUs. The weighted average fair value at grant date of the RSUs and PSUs was $10.04 , $8.95 , and $ 4.52 , for the years ended December 31, 2016, 2015, and 2014, respectively. The fair value of RSUs and PSUs vested for the years ended December 31, 2016, 2015, and 2014 was $1.6 million, $1.0 million, and $1.0 million, respectively. As of December 31, 2016, there was approximately $ 3.7 million of unrecognized compensation cost, net of forfeitures, related to non-vested RSUs and PSUs, which is expected to be recognized over a weighted average remaining period of approximately 1.31 years. ESPP As of December 31, 2016, 2,400,000 shares of the Company’s common stock are reserved for issuance under the Company’s ESPP. Under the terms of the ESPP, eligible employees may choose to have up to 15 % of their salary withheld to purchase the Company's common stock and may purchase up to 999 shares up to a maximum dollar limit of $6,250 per offering period. Each offering under the ESPP is for a three -month period. The purchase price of the stock issued under the ESPP will be equal to 85 % of the lower of the fair market value of a share of common stock on the first day of the offering or on the final day of the offering period. As of December 31, 2016, 2,398,138 shares of common stock were available for issuance under the ESPP. Repurchase of Common Stock The Company’s Board of Directors authorized an $ 80.5 million share repurchase program that expired December 31, 2015 . The Company repurchased and retired 1,526,306 and 3,822,434 shares at a cost of $12.8 million and $24.4 million, during the years ended December 31, 2015 and 2014, respectively, for a cumulative amount of $78.1 million in share repurchases repurchased under the repurchase program. Repurchased shares have been retired and constitute authorized but unissued shares. Upon repurchase, the Company eliminated the par value associated with the retired shares, and the excess price of the repurchase above par value was charged to retained earnings (accumulated deficit).

401(k) Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2016
401(k) Plan [Abstract]
401(k) Plan	Note 12 — 401(k) Plan The Company has a pre-tax and Roth savings plan covering most U.S. employees, which qualifies under Section 401(k) of the Internal Revenue Code. Under the plan, eligible employees may contribute a portion of their pre-tax or after-tax salary, subject to certain limitations. The Company contributes and matches 50 % of the employee contributions. Company contributions, which can be terminated at the Company's discretion, were approximately $0.2 million, $ 0.2 million, and $ 0.1 million for the years ended December 31, 2016, 2015, and 2014, respectively.

Licensing Agreements

Licensing Agreements	12 Months Ended
	Dec. 31, 2016
Licensing Agreements [Abstract]
Licensing Agreements	Note 13 — Licensing Agreements Theravance Biopharma, Inc. (“Theravance Biopharma”) In May 2015, Theravance Biopharma granted the Company exclusive development and commercialization rights to VIBATIV ® (telavancin) in China, Hong Kong, Macau, Taiwan and Vietnam, in exchange for upfront and regulatory milestone payments totaling $6 million. SciClone will be responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration. Theravance Biopharma will sell to SciClone all clinical and commercial product required to develop and commercialize VIBATIV in China and the Company’s other licensed territories. The Medicines Company In December 2014, the Company entered into a strategic partnership agreement that grants SciClone a license and exclusive rights for two cardiovascular products in China from The Medicines Company including 1) Angiomax ® (bivalirudin) for Injection for which a Phase 3 registration trial was completed in China . The Company has received Clinical Trial Application (“CTA”) approval and a Clinical Trial Waiver from the China Food and Drug Administration (“CFDA”) in December 2016, and are in the process of preparing a New Drug Application (“NDA”) , and 2) Cleviprex ® (clevidipine) In jectable Emulsion, for which a CTA for China was filed in 2013. The Company received CTA approval from the CFDA in early 2016 and are preparing a clinical study. As Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A. (“Chiesi”), acquired the rights to Cleviprex in June 2016 from The Medicines Company, SciClone will now be working together with Chiesi and The Medicines Company to progress the Cleviprex clinical study going forward. Under the terms of the agreement, which apply to Chiesi for Cleviprex, the Company will be responsible for all aspects of commercialization, including pre-and post-launch activities, for both products (Cleviprex and Angiomax) in the China market (excluding Hong Kong and Macao). The Company has also agreed to participate in the China registration process for both products. Financial terms of the agreements for the two products, in addition to net sales royalties payabl e to The Medicines Company and /or Chiesi, include the following additional payments to The Medicines Company and/or Chiesi: an upfront payment made in the fourth quarter of 2014; a project support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5 million. Zensun On May 13, 2013, the Company, through a designated affiliate, entered into a framework agreement with Zensun for the exclusive promotion, marketing, distribution and sale of Neucardin in China, Hong Kong and Macao. Neucardin is a novel, first-in-class therapeutic for the treatment of patients with intermediate to advanced heart failure, for which a NDA was submitted to and accepted for review by the CFDA in 2012. The CFDA informed Zensun in 2014 that its Phase 2 clinical study data is insufficient, and has asked Zensun to submit an NDA once the ongoing Phase 3 clinical study reaches its endpoints. The Zensun framework agreement provides the principal terms of the arrangement and the two parties have also entered into a supplemental license and supply agreement. Subject to certain conditions, the Company has agreed to make payments of up to $18.5 million to Zensun, consisting of an upfront payment amount and further amounts on the achievement of certain milestones, including the approval of an NDA for Neucardin , the granting of a manufacturing license, good manufacturing practices certificate and drug approval number in China. The Company has agreed under certain conditions to make milestone payments to Zensun of $10 million if approval is received for a new device to deliver Neucardin and up to $25 million if approval is re ceived for the use of Neucardin in additional indications. Zensun will be responsible for manufacture of the product and the Company has agreed to purchase the product exclusively from Zensun for the duration of the agreement. In addition, the Company agreed to provide a collateralized loan to Zensun of up to approximately $12.0 million. Refer to Note 6 “Loans Receivable” for further information on the loans to Zensun. For the years ended December 31, 2016, 2015 and 2014, the Company recorded upfront and milestone payments totaling $4.5 million, $ 7.5 million and $11.0 million, respectively, in research and development expense related to its licensing arrangements.

Termination of Collaboration wi

Termination of Collaboration with Cardiome Pharma Corp. (“Cardiome”)	12 Months Ended
	Dec. 31, 2016
Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”) [Abstract]
Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”)	Note 14 — Termination of Collaborati on with Cardiome Pharma Corp. (“ Cardiome”) In August 2015, Cardiome, from whom the Company licensed marketing and commercialization rights to the heart medication Aggrastat ® , and the Company mutually agreed to end their collaboration for Aggrastat and terminate the Company’s exclusive distributorship in China for the product, resulting in the Company’s obligation to return all rights to the product to Cardiome. The Company recorded Aggrastat revenues of $1.8 million and $1.1 million for the years ended December 31, 2015 and 2014, respectively, and the Company does not expect to generate any further Aggrastat revenues. The terms of the agreement include up to $750,000 in transition payments to be received by the Company from Cardiome over approximately a one year period and require Cardiome to repurchase Aggrastat inventory held by the Company at its original purchase price. Transition payments in the amount of $300,000 and $450,000 were collected from Cardiome during the third quarter of fiscal 2016 and the second half of fiscal 2015, respectively, and were recorded as a credit to general and administrative expenses. During the fourth quarter of 2015, the Company received $1.1 million from Cardiome for repurchased inventory. The Company recorded the $1.1 million for reimbursement for inventory returned as a reduction in cost of product sales since all of such inventory had previously been written down to zero . For the year ended December 31, 2015, the Company recorded a liability of $0.6 million, and a corresponding offset to revenue and cost of goods sold, related to Aggrastat product that it later repurchased from its customer in connection with the termination of its agreement with Cardiome. Under the terms of the agreement, Cardiome was not obliged to repurchase this inventory already sold to the Company’s distributors.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2016
Contingencies [Abstract]
Contingencies	Note 15 — Contingencies Legal Matters The Company is a party to various legal proceedings and was subject to government investigations, as noted in this section below. All legal proceedings and any government investigations are subject to inherent uncertainties, unfavorable rulings or other adverse events which could occur. Unfavorable outcomes could include substantial monetary damages or awards, injunctions or other remedies, and if any of these were to occur, the possibility exists for a material adverse impact on the Company’s business, results of operations, financial position, and overall trends. The Company might also conclude that settling one or more such matters is in the best interests of its stockholders and its business, and any such settlement could include substantial payments. As previously disclosed, since 2010 the SEC and the U.S. Department of Justice (“DOJ”) had each been conducting formal investigations of the Company regarding a range of matters, including the possibility of violations of the Foreign Corrupt Practices Act (“FCPA”), primarily related to certain historical sales and marketing activities with respect to the Company’s China operations. In response to these matters, the Company’s Board appointed a Special Committee of independent directors (the “Special Committee”) to oversee its response to the government inquiry. Based on an initial review, the Special Committee decided to undertake an independent investigation as to matters reflected in and arising from the SEC and DOJ investigations in order to evaluate whether any violation of the FCPA or other laws occurred. The Company previously recorded a charge to operating expenses in the fourth quarter of 2013 in the amount of $2.0 million for the accrual of an estimated loss associated with the SEC and DOJ investigations based on the available information at the time. In the second quarter of 2015, the Company recorded an additional charge to operating expenses of $10.8 million based on an agreement in principle reached with the SEC which had not yet been finalized, bringing the accrued liability to $12.8 million. On October 7, 2015, the Company deposited $12.8 million in an interest-bearing escrow account that it established related to the agreement in principle regarding a proposed settlement of FCPA-related matters with the staff of the SEC, creating a cash restriction at the time of deposit. On February 4, 2016, the Company announced that it entered into a settlement agreement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Under the terms of the settlement agreement, in February 2016 the Company paid to the SEC a total of $12.8 million which was released from its escrow account, including disgorgement, pre-judgment interest and a penalty as final settlement. This payment was in line with the charges the Company previously recorded and disclosed as summarized above. As part of the agreement the Company neither admitted nor denied engagement in any wrongdoing and the Company agreed to give status reports to the SEC for the next three years on its continued remediation and implementation of anti-corruption compliance measures. The DOJ has also completed its related investigation and has declined to pursue any action. NovaMed Shanghai was a party to a Distribution and Supply Agreement with MEDA Pharma GmbH & Co. KG (“MEDA”). Following the Company’s acquisition of NovaMed Shanghai, MEDA claimed it had a right to terminate the agreement under a change of control provision. NovaMed Shanghai does not believe that MEDA had a right of termination under the agreement. As of February 24, 2017, NovaMed Shanghai entered into a settlement agreement with MEDA to resolve all outstanding claims of each party under the Distribution and Supply Agreement, including as related to the China International Economic and Trade Arbitration Commission (“CIETAC”) arbitration in which NovaMed Shanghai had been claiming for remuneration of services and for certain reimbursement amounts. Per the terms of the settlement agreement, MEDA shall pay NovaMed Shanghai $83,333 , and NovaMed Shanghai shall withdraw its “Request for Second Arbitration” with CIETAC.

Credit Facility

Credit Facility	12 Months Ended
	Dec. 31, 2016
Credit Facility [Abstract]
Credit Facility	Note 16 — Credit Facility In December 2013, the Company’s subsidiary, NovaMed Shanghai entered into a 10.0 million RMB revolving line of credit facility (approximately $1.6 million USD) and a maximum 15.0 million RMB loan facility (approximately $2.4 million USD) with Shanghai Pudong Development Bank Co. Ltd. (“the Credit Facility”) that was secured by its accounts receivable. The Credit Facility bore interest on borrowed funds at the People’s Bank of China 6-month base rate plus 15% ( 6.44% in 2014) on outstanding balances. The Credit Facility expired November 30, 2014 , and all amounts borrowed were repaid by the expiration date. For the year ended December 31, 2014, the Company paid interest of approximately $48,000 related to the Credit Facility.

Segment Information And Geograp

Segment Information And Geographic Data	12 Months Ended
	Dec. 31, 2016
Segment Information And Geographic Data [Abstract]
Segment Information And Geographic Data	Note 17 — Segment Information and Geographic Data The Company reports segment information based on the internal reporting used by management for evaluating segment performance based on management’s estimates of the appropriate allocation of resources to segments. T he Company operates and manages its business primarily on a geographic basis. Accordingly, the Company determined its operating segments and reporting units, which are generally based on the nature and location of its customers, to be 1) China, and 2) Rest of the World, including the U.S. and Hong Kong. The Company evaluates the performance of its operating segments based on revenues and operating income (loss). Revenues for geographic segments are generally based on the location of customers. Operating income (loss) for each segment includes revenues, related cost of sales and operating expenses directly attributable to the segment. Operating income (loss) for each segment excludes non-operating income and expense. Summary information by operating segments is as follows ( in thousands ):    For the Year Ended December 31,   2016 2015 2014  Revenue:  China $ 152,563 $ 151,573 $ 130,311  Rest of the World (including the U.S. and Hong Kong) 7,533 5,684 4,479  Total net revenues $ 160,096 $ 157,257 $ 134,790  Income (loss) from operations:  China $ 57,202 $ 52,892 (2) $ 35,630 (4)  Rest of the World (including the U.S. and Hong Kong) (23,967) (1) (22,981) (3) (9,646)  Total income from operations $ 33,235 $ 29,911 $ 25,984  Non-operating income (expense):  China $ 885 $ 349 $ 412  Rest of the World (including the U.S. and Hong Kong) 13 10 (19)  Total non-operating income $ 898 $ 359 $ 393  Income (loss) before provision for income tax:  China $ 58,087 $ 53,241 $ 36,042  Rest of the World (including the U.S. and Hong Kong) (23,954) (22,971) (9,665)  Total income before provision for income tax $ 34,133 $ 30,270 $ 26,377 (1) Operating loss for the Rest of the World segment for the year ended December 31, 2016 includes upfront and milestone payments totaling $4.5 million related to the Company’s licensing arrangements. (2) Operating income for the China segment for the year ended December 31, 2015 includes upfront and milestone payments totaling $5.5 million related to the Company’s licensing arrangements. (3) Operating loss for the Rest of the World segment for the year ended December 31, 2015 includes a milestone payment totaling $2.0 million related to the Company’s licensing arrangements. Operating loss for the Rest of the World segment also includes $10.8 million of expense that the Company recorded for the year ended December 31, 2015 associated with the SEC settlement related to the Company’s investigations with the SEC and DOJ. Refer to Note 15 for further information regarding the SEC and DOJ investigations. (4) Operating income for the China segment for the year ended December 31, 2014 includes upfront payments totaling $11.0 million related to the Company’s licensing arrangements.  Long-lived assets by operating segment are as follows ( in thousands ):   December 31,  Long-lived assets: 2016 2015  China $ 44,603 $ 46,315  Rest of the World (including the U.S. and Hong Kong) 1,562 1,783  Total long-lived assets $ 46,165 $ 48,098  

Selected Quarterly Financial Da

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data	N ote 18 — Selected Quarterly Financial Data (unaudited)     Three Months Ended   (in thousands, except per share amounts)  March 31, June 30, September 30, December 31,  2016 2016 2016 2016  Product sales, net $ 35,320 $ 37,869 $ 39,457 $ 43,291  Promotion services revenue 1,179 1,122 1,087 771  Cost of product sales 5,813 5,712 5,585 5,788  Net income 7,864 6,338 (1) 10,116 (2) 6,411 (3)  Basic net income per share $ 0.16 $ 0.13 $ 0.20 $ 0.13  Diluted net income per share $ 0.15 $ 0.12 $ 0.19 $ 0.12      Three Months Ended   (in thousands, except per share amounts)  March 31, June 30, September 30, December 31,  2015 2015 2015 2015  Product sales, net $ 33,168 $ 37,202 $ 41,986 $ 41,973  Promotion services revenue 400 744 894 890  Cost of product sales 4,597 5,681 6,853 5,217 (5)  Net income 8,962 (4,022) (4) 11,979 12,544 (5)  Basic net income (loss) per share $ 0.18 $ (0.08) $ 0.24 $ 0.25  Diluted net income (loss) per share $ 0.17 $ (0.08) $ 0.23 $ 0.24  (1) During the three months ended June 30, 2016, the Company recorded upfront payments totaling $2.0 million in research and development expense related to its licensing arrangements. (2) During the three months ended September 30, 2016, the Company recorded a milestone payment totaling $0.2 million in research and development expense related to its licensing arrangements. (3) During the three months ended December 31, 2016, the Company recorded milestone payments totaling $2.3 million in research and development expense related to its licensing arrangements. (4) During the thre e months ended June 30, 2015, the Company recorded upfront payments totaling $5.5 million in research and development expense related to its licensing arrangements. In addition, during the three months ended June 30, 2015, the Company recorded an additional charge of $10.8 million of operating expense, in addition to the $2.0 million charge recorded in the fourth quarter of 2013, to reflect the Company’s total SEC settlement expense of $12.8 million. Refer to Note 15 for more information on the SEC and DOJ investigations. (5) During the three months ended December 31, 2015, the Company recorded a milestone payment totaling $2.0 million in research and development expense related to its licensing arrangements, and recorded a $1.1 million and $0.3 million reduction to cost of product sales and general and administrative expense, respectively, related to return of inventory and other items as part of its termination of collaboration with Cardiome. Refer also to Note 14 for more information related to this termination.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2016
Subsequent Event [Abstract]
Subsequent Event	Note 19 — Subsequent Event As of February 24, 2017, NovaMed Shanghai entered into a settlement agreement with MEDA to resolve all outstanding claims of each party under the Distribution and Supply Agreement, including as related to the CIETAC arbitration in which NovaMed Shanghai had been claiming for remuneration of services and for certain reimbursement amounts. Per the terms of the settlement agreement, MEDA shall pay NovaMed Shanghai $83,333 , and NovaMed Shanghai shall withdraw its “Request for Second Arbitration” with CIETAC. As part of the settlement agreement, neither party admitted any liability or wrongdoing. For further information on this matter, refer to Note 15 regarding MEDA .

Schedule II - Valuation And Qua

Schedule II - Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Schedule II - Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation And Qualifying Accounts	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS SCICLONE PHARMACEUTICALS, INC. Receivables and Product Returns Reserves ( in thousands ):    Balance at Charges for Deductions for Deductions for Balance at  Beginning of Amounts Amounts Amounts End of  Period Reserved Recovered (1) Written Off Period  Receivables Reserve:  Year Ended December 31, 2016 $ (594) $ — $ 500 $ 94 $ —  Year Ended December 31, 2015 $ (998) $ (541) $ 400 $ 545 $ (594)  Year Ended December 31, 2014 $ (3,587) $ — $ 1,500 $ 1,089 $ (998)    Balance at Charges for Deductions for Deductions for Balance at  Beginning of Amounts Amounts Amounts End of  Period Reserved Recovered Paid Period  Reserve for Product Returns:  Year Ended December 31, 2016 $ (134) $ (155) $ — $ — $ (289)  Year Ended December 31, 2015 $ (66) $ (134) $ — $ 66 $ (134)  Year Ended December 31, 2014 $ — $ (66) $ — $ — $ (66)    (1) Recorded as a gain to general and administrative expense.

The Company And Summary Of Si28

The Company And Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2016
The Company And Summary Of Significant Accounting Policies [Abstract]
Description Of Business	Description of Business SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”), incorporated in 1990, is a United States (“U.S.”)-headquartered, China-focused, specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company’s lead product, ZADAXIN ® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately 7 partnered and in-licensed products in China. SciClone is also pursuing the registration of several other therapeutic products in China.
Presentation	Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated from the consolidated financial statements.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make informed estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates.
Cash Equivalents And Investments	Cash Equivalents and Investments Cash equivalents consist of highly liquid investments with original maturities of three months or less on the date of purchase. The Company records its investments at fair value, as determined by available information on the consolidated balance sheet date. The Company’s cash investment portfolio as of December 31, 2016 consisted of money market funds that were included in cash and cash equivalents. As of December 31, 2016, the Company’s investment portfolio also included an available-for-sale investment in the common stock of a third party (No te 5) categorized within Level 2 of the fair value hierarchy. The Company records unrealized gains or losses on available-for-sale equity investments in other comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale equity investments are included in earnings. Available-for-sale investments are evaluated for impairment each reporting period. An investment is considered impaired if the fair value of the investment is less than its cost. If, after consideration of all available evidence to evaluate the realizable value of its investment, impairment is determined to be other-than-temporary, then an impairment loss is recognized in the consolidated statement of operations. No such losses were recorded in the periods presented.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. The three levels of input are: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Where quoted prices are available in an active market, the Company determines fair value based on quoted market prices, and classifies these values in level 1 of the valuation hierarchy. If quoted market prices are not available, fair values are based on observable inputs such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities and are classified in level 2 of the valuation hierarchy. When quoted prices and observable inputs are unavailable, fair values are based on cash flow models and are classified in level 3 of the valuation hierarchy. The cash flow models use inputs specific to the asset or liabilities including estimates for interest rates and discount rates including yields of comparable traded instruments adjusted for illiquidity and other risk factors, amount of cash flows and expected holding periods of the assets and liabilities. These inputs reflect the Company’s assumptions about the assumptions market participants would use in pricing the assets and liabilities including assumptions about risk developed based on the best information available in the circumstances. The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment, and may materially affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. The Company’s policy is to recognize transfers between levels as of the date of the event or change in circumstance that caused the transfer. Other financial instruments, including accrued short-term liabilities, are carried at cost, which the Company believes approximates fair value because of the short-term maturity of these instruments.
Concentration Of Risk	Concentration of Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, accounts receivable, and loans receivable. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents, and by customers and partners in the event of default by the customer or partner to pay the amounts due to the Company on receivables and loans receivables, respectively, to the extent of the amounts recorded on the consolidated balance sheet. Most of the Company’s cash and cash equivalents are held by financial institutions that the Company believes are of high credit quality. At times, deposits may exceed government insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company is exposed to risk of its investment in the common stock of a third party losing market value. In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN, the Company manufactures its product using its U.S. and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Holding Lingyun Biopharmaceutical (Shanghai) Co. Limited (“Sinopharm”). Sinopharm acts as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for replacement of product in the events of damaged product or quality control issues. As the Company bears risk of loss until delivery has occurred, revenue is not recognized until the shipment reaches its destination. After the Company’s sale of ZADAXIN to the importer, Sinopharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier (“Tier 2”) distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier (“Tier 3”) local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors. Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers. Sinopharm contributed 93% , 97% and 94% of the Company’s total net revenue for the years ended December 31, 2016, 2015 and 2014, respectively, which revenues related to the Company’s China segment. There were no other customers that exceeded 10% of the Company’s total net revenue in those years. Total ZADAXIN product sales were $150.1 million or 96% , $146.1 million or 95% , and $126.1 million or 96% , of total product sales for the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, approximately $ 39.5 million, or 95 %, of the Company's gross accounts receivable was attributable to one customer, Sinopharm, in China. The Company generally does not require collateral from its customers. The Company maintains reserves for potential credit losses and such actual losses may vary significantly from its estimates. The Company currently relies on two suppliers to provide key components to its ZADAXIN manufacturing supply. Although there are a limited number of manufacturers who would be able to meet the requirements to manufacture these components, the Company believes that other suppliers could provide similar components on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which would affect operating results adversely. Per the Company’s previous contractual arrangement with Sinopharm through December 31, 2015, and a renewed contractual arrangement with Sinopharm (the Company’s sole distributor for ZADAXIN in China) which took effect January 1, 2016, the Company’s sales of ZADAXIN to Sinopharm were denominated in U.S. dollars through June 30, 2016. However, the established importer price was adjusted quarterly based upon exchange rate fluctuations between the U.S. dollar and Chinese Yuan Renminbi (“RMB”) . Effective July 1, 2016, the Company’s sales of ZADAXIN to Sinopharm are and will be denominated in RMB. A significant portion of the Company’s other revenues and expenses are also denominated in RMB and a significant portion of the Company’s assets and liabilities are denominated in RMB and all are exposed to foreign exchange risk. In the recent year and months, the RMB has experienced devaluation. Such devaluation negatively affects the U.S. dollar value of revenues while it positively affects the U.S. dollar value of China operating expenses. RMB is not freely convertible into foreign currencies. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions at the exchange rates quoted by the People’s Bank of China. Remittances in currencies other than RMB by the Company in China require certain supporting documentation in order to process the remittance.
Accounts Receivable Reserve	Accounts Receivable Reserve The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are charged off at the point when they are considered uncollectible. As of December 31, 2016, the Company determined no bad debt reserve was necessary. As of December 31, 2015, the Company had a receivable reserve of $0.5 million related to accounts receivable from one customer that was more than one year past due. During 2014, the Company’s subsidiary, SciClone Pharmaceuticals International China Holding Ltd (“SPIL China”) executed an agreement with this customer providing for settlement of the receivable balance, which at the time was $3.0 million. The terms of the settlement agreement resulted in the write-off of $1.1 million in previously fully reserved accounts receivable with an equivalent charge-off of the allowance for bad debt, which had no impact on net income in 2014. Of the remaining $1.9 million receivable balance, $0.5 million, $0.4 million and $1.0 million were collected in 2016, 2015 and 2014, respectively, per the terms of the settlement agreement, and these gains on recovery were recorded as reductions to general and administrative expense for those years. The Company recognized $0.5 million of bad debt expense in general and administrative expense during the first quarter of 2015 related to past due receivables from another customer due to uncertainty regarding the collectability of the customer’s outstanding receivable balance. The Company wrote-off the $0.5 million of past due accounts receivable from this customer during the fourth quarter of 2015 as uncollectible.
Inventories	Inventories Inventories consist of raw materials, work in progress and finished goods products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the impairment is first indicated. During the years ended December 31, 2016, 2015, and 2014, the Company recorded inventory write-downs of $34,000 , $0 , and $2.1 million, respectively, principally related to carrying value reductions for excess Aggrastat ® product in the 2014 period. As of December 31, 2016, there was zero remaining Aggrastat product in inventory following a discontinuation of the product. (Refer to Note 14 for further information regarding the discontinuation of Aggrastat.)
Property And Equipment	Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recorded over the estimated useful lives of the respective assets on the straight-line basis. Office furniture and fixtures are generally amortized over five years, office equipment and computer software are generally amortized over three years, and the Company’s vehicle is being amortized over four years. Leasehold improvements are amortized over the shorter of the estimated useful life or lease term on the straight-line basis. The Company’s policy is to identify and record impairment losses, if necessary, on property and equipment when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.
Goodwill	Goodwill The Company accounted for the acquisition of NovaMed Pharmaceuticals, Inc. (“NovaMed”) in 2011 under the acquisition method of accounting in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 805, Business Combinations . Under the acquisition method of accounting, the total acquisition-date fair value of the assets and liabilities are recognized as of the closing date. The excess of the fair value of the total consideration transferred over the acquisition-date fair value of net tangible and intangible assets and liabilities assumed was allocated to goodwill. Goodwill is tested for impairment at least annually, or whenever events or circumstances occur that indicate impairment might have occurred in accordance with ASC Topic 350, Intangibles — Goodwill and Other . Goodwill relates to the Company’s China segment which focuses on the Company’s primary pharmaceutical distribution market , consisting of the NovaMed business and the legacy China business, which represent a single reporting unit. As of December 31, 2016, 2015 and 2014, the Company tested its goodwill for impairment by quantitatively comparing the fair value of the reporting unit to its carrying amount - step one of the two-step impairment test. The Company bypassed the optional qualitative screening test in proceeding directly to step one of the two-step impairment test. The Company estimates the fair value of the China reporting unit using a discounted cash flow model. This valuation approach considers a number of factors that include, but are not limited to, expected future cash flows, growth rates, discount rates, and requires the Company to make certain assumptions and estimates regarding industry economic factors and future profitability of the Company’s business. If the Company determines that the carrying value of its reporting unit exceeds its fair value, the Company would then calculate the implied fair value of the reporting unit goodwill as compared to its carrying value to determine the appropriate impairment charge. After completing the Company’s impairment review for the reporting unit as of December 31, 2016, 2015, and 2014, the Company concluded that goodwill was not impaired in any of these years.
Loans Receivable	Loans Receivable Loans receivable are due from a single third party (see Note 6). Loans are initially recorded, and continue to be carried, at unpaid principal balances under “other assets” on the consolidated balance sheet. Carried balances are subsequently adjusted for payments of principal or adjustments to the allowance for loan losses to account for any impairment. Interest income is recognized over the term of the loans and is calculated using the simple-interest method, as the loans do not have associated premium or discount. If the loans were to experience impairment, interest income would not be recognized unless the likelihood of further loss was remote. Although the measurement basis is unpaid principal (as adjusted for subsequent payments or impairment), not fair value, the loans receivable would qualify as Level 3 measurements under the fair value hierarchy (Note 2) due to the presence of significant unobservable inputs related to the counterparty, which is a private entity. Management considers impairment to exist when, based on current information or factors (such as payment history, value of collateral, and assessment of the counterparty’s current creditworthiness), it is probable that principal and interest payments will not be collected according to the contractual agreements. Management considers a loan payment delinquent when not received by the due date. As of December 31, 2016 and 2015, management concluded the loans receivable were not impaired, and there was no allowance for loan losses.
Accrued Expenses	Accrued Expenses The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to them. Examples of estimated accrued expenses include fees paid to contract research organizations and investigative sites in connection with clinical trials, fees paid to contract manufacturers in connection with the production of materials, and professional services. The Company periodically confirms the accuracy of its estimates with selected service providers and makes adjustments, if necessary, in the periods identified. Expenses related to clinical trials charged to research and development expense generally are accrued based on estimates of work performed or the level of patient enrollment and activities according to the protocols and agreements. The Company makes adjustments, if necessary, in the periods identified to reflect actual levels of work performed, and such adjustments have historically not been material. T he financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under certain contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses to the actual services received and efforts expended. The Company monitors planned protocols, work performed, patient enrollment levels and related activities to the extent possible and adjusts estimates accordingly. The Company records as liabilities estimated amounts for litigation, claims or other legal actions that are probable and can be reasonably estimated. The likelihood of a material change in these estimated reserves is dependent on the possible outcome of settlement negotiations, regulatory or judicial review and the development of facts and circumstances in extended litigation which could change claims or assessments when both the amount and range of loss on some outstanding litigation is uncertain. The Company discloses in the footnotes to the financial statements when it is unable to make a reasonable estimate of a material liability that is reasonably possible to result from unfavorable outcomes. As events occur, the Company assesses the potential liability related to any pending litigation, claims or other legal actions and adjusts its estimates accordingly. Such adjustments could materially impact its financial statements.
Foreign Currency Translation	Foreign Currency Translation The Company translates the assets and liabilities of its foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using average rates of exchange in effect during the period. Goodwill, and certain other balances, are generally recorded in the local currency which is the functional currency of the Company’s subsidiaries located in China. As a result, the carrying value of goodwill and certain other balances may fluctuate with the value of the RMB as compared to the U.S. dollar. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of stockholders' equity. The Company records foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction losses were $2.2 million and $0.4 million for the year ended December 31, 2016 and 2015, respectively. For the year ended December 31, 2014 foreign currency transaction gains and losses were not significant.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured. Product Revenue. The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to Sinopharm are recognized upon arrival of a shipment to its destination, which marks the point when title and risk of loss to product are transferred. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors. Effective January 1, 2016, the Company’s new contractual arrangement with its China importer and distributor for ZADAXIN, Sinopharm, is resulting in the later recognition (relative to practices prevailing under the old contractual arrangement through December 31, 2015) of a portion of the Company’s revenue due from Sinopharm related to situations where the provincial tender price is greater relative to a reference (baseline) tender price. The tender price is the ultimate retail end price approved by provincial authorities. There is a price mechanism in the new contractual arrangement whereby Sinopharm is invoiced at a lower base price relative to that prevailing in the previous agreement. The lower base price (reduced by estimated price compensation payable to Sinopharm for situations where the provincial tender price is lower than the reference (baseline) tender price) is recorded as revenue at the time the sale is completed upon arrival at destination. To date, there are no situations where a provincial tender price is less than the reference (baseline) tender price. Sinopharm is invoiced for the portion of the price that results from situations where the provincial tender price is greater than the reference (baseline) tender price at a later time, and such amount is recognized as revenue after the amount has been agreed to with them. It is expected that the price compensation due to the Company related to sales in a quarter under the price adjustment mechanism for provinces with tender prices above the reference (baseline) tender price will continue to be recognized on a rolling one-to-two quarter delayed basis relative to the originating sales quarter. Promotion Services Revenue. The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in a promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. Revenue Reserve . The Company generally maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which are based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired or are deemed to be damaged or defective when delivered upon arrival at destination. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of December 31, 2016 and 2015, the Company’s revenue reserves were $0.3 million and $0.1 million, respectively, on its consolidated balance sheets. The Company evaluates the need for a returns reserve quarterly and adjusts it when events indicate that a change in estimate is appropriate. Changes in estimates could materially affect the Company’s results of operations or financial position. It is possible that the Company may need to adjust its estimates in future periods.
Sales Tax And Surcharge Expense	Sales Tax and Surcharge Expense Sales taxes and surcharge costs are expensed as incurred and are included in sales and marketing expense. The Company is generally subject to a 5 - 6.42 % business tax and surcharge for services provided related to marketing products under the relevant taxation laws in China. Sales tax and surcharge costs amounted to approximately $3.8 million, $3.4 million, and $ 2.5 million for the years ended December 31, 2016, 2015, and 2014, respectively.
Research And Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. These costs include salaries and other personnel-related expenses, including associated stock-based compensation, facility-related expenses, depreciation of facilities and equipment, upfront and milestone payments under in-licensing agreements with certain business partners and other license-related fees, and services performed by clinical research organizations and research institutions and other outside service providers.
Shipping And Handling Costs	Shipping and Handling Costs Shipping and handling costs incurred for inventory purchases and product shipments are included in cost of product sales for all periods presented.
Advertising Expenses	Advertising Expenses Advertising costs are expensed as incurred and are included in sales and marketing expenses for all periods presented. Advertising expenses for the years ended December 31, 2016, 2015, and 2014, were $1.7 million, $ 4.1 million, and $2.6 million, respectively.
Legal Costs	Legal Costs Legal costs related to loss contingencies are expensed to general and administ rative expense as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation costs relating to share-based payment transactions, including stock options, restricted stock units (“RSUs”), performance restricted stock units (“PSUs”) and the employee stock purchase plan (“ESPP”). Stock-based compensation expense for stock options and the employee stock purchase plan is estimated at the date of grant based on the fair value of the award using the Black-Scholes option-pricing model. Stock-based compensation expense for RSUs and PSUs are estimated at the date of grant based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. Stock-based compensation expense values for stock options, RSUs and the ESPP are recognized as expense on a straight-line basis over the requisite service period, net of estimated forfeitures. The stock-based compensation costs that are ultimately expected to vest are recognized as expense ratably (as the awards vest) over the requisite service period, which is generally one or four years for stock options and RSUs and three months for the ESPP. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The total expense recognized over the vesting period will only be for those awards that ultimately vest. The Company recognizes expense related to the PSUs and performance stock options over the implicit service period if it is probable that the performance goals will be achieved. If it is subsequently determined that the performance goals are not probable of achievement, the expense related to the PSUs or performance stock options is reversed.
Income Taxes	Income Taxes Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more-likely-than-not that the deferred tax assets will not be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made. The Company records liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period. The Company’s policy is to recognize interest and penalties related to the liabilities for uncertain tax positions as a component of income tax expense. The amount of accrued interest related to tax positions taken on the Company’s tax returns and included in accrued and other current liabilities was $1.7 million as of December 31, 2016 and 2015. The amount of interest recognized as tax expense related to uncertain tax positions in the consolidated statements of income was $0.1 million, $0.2 million and $0.3 million for the years ended December 31, 2016, 2015 and 2014, respectively.
Net Income Per Share	Net Income Per Share Basic net income per share has been computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted net income per share is computed by dividing net income by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income per share includes any dilutive impact from outstanding stock options, stock awards and the ESPP using the treasury stock method. The following is a reconciliation of the numerator and denominators of the basic and diluted net income per share computations for the years ended December 31 (in thousands, except per share amounts):     2016 2015 2014   Numerator:  Net income $ 30,729 $ 29,463 $ 25,208  Denominator:  Weighted-average shares outstanding used to compute basic net income per share 50,235 49,797 51,277  Effect of dilutive securities 2,331 2,376 1,407  Weighted-average shares outstanding used to compute diluted net income per share 52,566 52,173 52,684  Basic net income per share $ 0.61 $ 0.59 $ 0.49  Diluted net income per share $ 0.58 $ 0.56 $ 0.48  For the years ended December 31, 2016, 2015, and 2014, approximately 2,207,440, 1,151,537 , and 3,541,071 shares, respectively, related to outstanding stock options and awards were excluded from the calculation of diluted net income per share because the effect from the assumed exercise or issuance of these options or awards calculated under the treasury stock method would have been anti-dilutive. In addition, for the years ended December 31, 2016, 2015, and 2014, outstanding stock options and awards for 275,000 , 312,500 , and 50,000 shares, respectively, subject to performance conditions were excluded from the calculation of diluted net income per share because the performance criteria had not been or were not probable to be met.
Segment Information	Segment Information The Company operates in two segments (refer to Note 17).
Error Correction	Error Correctio n The Company provided $1.3 million of additional income tax expense, and recorded a corresponding accrual in accrued and other current liabilities, during the year ended December 31, 2016 to correct an error. The error correction reflected the recognition of a previously unrecognized liability for uncertain tax positions related to the potential nondeductibility, under the People’s Republic of China (“PRC”) tax regulations, of certain marketing costs related to the Company’s China operations. The adjustment related to tax years 2013 to 2015 and reflected the estimated tax exposure for each year as well as accrued interest thereon; such tax and interest amounts were $0.4 million, $0.5 million, and $0.4 million for the full years 2013, 2014, and 2015, respectively. The Company’s management evaluated the effects of the error on each prior annual and interim period, as well as the total error accumulated at the end of each respective prior period, and concluded under both approaches that the effects of the error were not material to previously issued annual or interim financial statements. The Company’s management also evaluated the total amount of the error correction in relation to actual results for full year 2016 and concluded the impact was not material to the 2016 financial statements . Accordingly, the total adjustment was recorded as an out-of-period adjustment in 2016.
New Accounting Standards Updates	New Accounting Standards Updates In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, "Revenue from Contracts with Customers (Topic 606)" , which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 is effective for the Company’s fiscal year beginning January 1, 2018, which reflects a one year deferral approved by the FASB in July 2015, with early application permitted provided that the effective date is not earlier than the original effective date. The Company is currently undertaking an assessment of its revenue contracts to determine what impact, if any, the adoption of ASU 2014-09 will have on its financial statements and related disclosures. The Company anticipates the impact of ASU 2014-09 will likely be limited to the timing of recognition of its variable consideration. This variable consideration arises from situations where the Company’s exclusive distributor in China is invoiced for the portion of the price that results from situations where the provincial tender price is greater than the reference (baseline) tender price at a later time subsequent to the original sale. Such amount is currently recognized as revenue after the amount has been agreed to with the distributor in a later quarter relative to the originating sales quarter. The timing of the recognition of such amounts may be earlier under the new guidance; the Company plans to finalize its assessment in early 2017. The standard permits the use of either the full retrospective or modified retrospective transition method. The Company has not yet selected a transition method. In November 2015, the FASB issued ASU 2015-17, " Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes”. This ASU amends existing guidance to require that deferred income tax liabilities and assets be classified as noncurrent in a classified balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified balance sheet. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted as of the beginning of an interim or annual period. Additionally, the new guidance may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company plans to apply the new guidance retrospectively. The impact of adopting this guidance is not expected to be material to the consolidated financial statements given the Company’s deferred tax amounts. In January 2016, the FASB issued ASU 2016-01, “Financial Instruments (Topic 825): Recognition and Measurement of Financial Assets and Liabilities” . The amended guidance (i) requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income; (ii) eliminates the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is currently required to be disclosed for financial instruments measured at fair value; (iii) requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments and (iv) requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, or calendar 2018 for the Company. The amended guidance should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The Company has evaluated the impact of adoption of this guidance on its consolidated financial statements and has concluded that the impact will be limited to a cumulative-effect adjustment for its investment in the common stock of a third-party which is currently classified as an available-for-sale equity investment, as well as prospective recognition of changes in the fair value of such investment, to the extent the Company continues to own the investment, as a component of net income. In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) ”. Under the new guidance, lessees will be required to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on the balance sheet. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for the Company from calendar 2019 and from the first interim period of calendar 2019, with earlier application permitted. The Company is evaluating the impact of the adoption of this update on its consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-09, “Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The Company currently plans to implement this ASU as required in the first quarter of calendar 2017. The Company does not expect that the adoption will have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ” This ASU requires a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The standard is effective for the Company from calendar 2020, with early adoption permitted for calendar 2019. The Company has yet to commence an evaluation of the impact of the adoption of this standard on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (Topic 230)." Current GAAP is unclear or does not include specific guidance on how to classify certain transactions in the statement of cash flows. This ASU is intended to reduce diversity in practice in how eight particular transactions are classified in the statement of cash flows. ASU No. 2016-15 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, provided that all of the amendments are adopted in the same period. Entities will be required to apply the guidance retrospectively. If it is impracticable to apply the guidance retrospectively for an issue, the amendments related to that issue would be applied prospectively. As the likelihood of the Company experiencing one or more of the eight particular specified transactions is low, ASU 2016-15 is not expected to have a material impact on the Company's consolidated financial statements . In January 2017, the FASB issued ASU 2017-04, " Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment " (Topic 350) , which removes the requirement to perform a “Step 2” hypothetical purchase price allocation to measure goodwill impairment if “Step 1” of the traditional two-step goodwill impairment model is failed. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value (the determination from “Step 1”), not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for us for annual and interim periods beginning January 1, 2020, with early adoption permitted, and applied prospectively. ASU 2017-04 will impact our goodwill balance to the extent such goodwill balance exists at the adoption date and to the extent that the fair value of our China reporting unit is less than its carrying value.

The Company And Summary Of Si29

The Company And Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
The Company And Summary Of Significant Accounting Policies [Abstract]
Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income Per Share Computations	   2016 2015 2014   Numerator:  Net income $ 30,729 $ 29,463 $ 25,208  Denominator:  Weighted-average shares outstanding used to compute basic net income per share 50,235 49,797 51,277  Effect of dilutive securities 2,331 2,376 1,407  Weighted-average shares outstanding used to compute diluted net income per share 52,566 52,173 52,684  Basic net income per share $ 0.61 $ 0.59 $ 0.49  Diluted net income per share $ 0.58 $ 0.56 $ 0.48 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Measurements [Abstract]
Financial Assets And Liability Measured At Fair Value On A Recurring Basis	   Fair Value Measurements as of December 31, 2016 Using   Quoted Prices in Significant  Active Markets Other Significant  for Observable Unobservable Balance  Identical Assets Inputs Inputs as of  Description (Level 1) (Level 2) (Level 3) December 31, 2016  Money market funds $ 19,701 $ — $ — $ 19,701  Common stock investment in third party (Note 5) — 794 — 794  Total $ 19,701 $ 794 $ — $ 20,495       Fair Value Measurements as of December 31, 2015 Using   Quoted Prices in Significant  Active Markets Other Significant  for Observable Unobservable Balance  Identical Assets Inputs Inputs as of  Description (Level 1) (Level 2) (Level 3) December 31, 2015  Money market funds $ 19,678 $ — $ — $ 19,678  Total $ 19,678 $ — $ — $ 19,678   

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Schedule Of Inventories	   December 31,  2016 2015  Raw materials $ 5,304 $ 3,871  Work in progress 498 535  Finished goods 10,785 6,570  Total $ 16,587 $ 10,976  

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property And Equipment [Abstract]
Schedule Of Property And Equipment	   December 31,  2016 2015  Construction in process $ 14 $ 18  Office equipment 3,363 3,172  Leasehold improvements 1,513 1,281  Office furniture and fixtures 1,320 1,377  Software 936 897  Vehicle 81 67  Gross property and equipment 7,227 6,812  Less accumulated depreciation (5,225) (4,161)  Net property and equipment $ 2,002 $ 2,651  

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill [Abstract]
Schedule Of Change In Goodwill	   Balance as of January 1, 2014 $ 35,357  Translation adjustments (836)  Balance as of December 31, 2014 $ 34,521  Translation adjustments (1,542)  Balance as of December 31, 2015 $ 32,979  Translation adjustments (2,141)  Balance as of December 31, 2016 $ 30,838 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	   December 31,   2016 2015  Accrued SEC settlement loss (Note 15) $ — $ 12,826  Accrued sales and marketing expenses 8,623 8,511  Accrued taxes, tax reserves and interest 5,335 4,323  Accrued compensation and benefits 5,140 4,341  Accrued professional fees 1,298 1,130  Accrued manufacturing costs 715 444  Other 1,685 576  Total $ 22,796 $ 32,151 

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies [Abstract]
Schedule Of Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements	   Minimum Lease  Year ended: Payments  2017 $ 2,311  2018 1,062  2019 267  2020 —  2021 —  $ 3,640 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Schedule Of Domestic And Foreign Components Of Income (Loss)	  2016 2015 2014  Domestic $ (8,363) $ (17,017) $ (8,496)  Foreign 42,496 47,287 34,873  Pre-tax income $ 34,133 $ 30,270 $ 26,377 
Schedule Of Effective Income Tax Rate Reconciliation	   2016 2015 2014  Tax at federal statutory rate $ 11,605 $ 10,382 $ 8,968  Foreign income taxed at different rates (11,712) (15,210) (10,788)  Federal tax effect of dividend from foreign subsidiary 2,999 4,317 —  Effect of uncertain tax positions 667 (126) 127  Change in valuation allowance (199) 1,092 2,672  Stock-based compensation (604) (86) 2  Nondeductible expenses 247 189 189  Other 401 249 (1)  Provision for income tax $ 3,404 $ 807 $ 1,169  
Schedule Of Components Of Income Tax Expense (Benefit)	   2016 2015 2014  Federal $ — $ — $ —  State 1 1 1  Foreign 3,103 793 1,489  Total current 3,104 794 1,490  Federal — — —  State — — —  Foreign 300 13 (321)  Total deferred 300 13 (321)  Provision for income tax $ 3,404 $ 807 $ 1,169  
Schedule Of Deferred Tax Assets And Liabilities	   2016 2015  Deferred tax assets:  Net operating loss carryforwards $ 36,938 $ 38,679  Research and development credit carryforwards 10,719 10,650  Intangibles 530 382  Other 2,543 2,692  Gross deferred tax assets 50,730 52,403  Valuation allowance (50,730) (52,104)  Total deferred tax assets — 299  Deferred tax liabilities:  Other — —  Total deferred tax liabilities — —  Net deferred tax assets $ — $ 299  
Schedule Of Unrecognized Tax Benefits	   2016 2015 2014  Balance beginning of period $ 5,470 $ 5,876 $ 6,138  Tax positions related to current year:  Additions for current year items 25 14 32  Additions for prior year items (see Note 1) 1,009 — —  Lapse of statute of limitations (604) (288) (206)  Changes for foreign currency translation (117) (132) (88)  Balance end of period $ 5,783 $ 5,470 $ 5,876  

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity [Abstract]
Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Income	   For the Year Ended December 31,   2016 2015 2014  Sales and marketing $ 984 $ 869 $ 1,031  Research and development 336 210 104  General and administrative 5,113 3,362 2,330  $ 6,433 $ 4,441 $ 3,465  
Schedule Of Valuation Assumptions Used For Stock Options And ESPP Plans	   2016 2015 2014  Risk-free interest rate:  Time-based stock options 1.41 % 1.52 % 1.61 %  Performance-based stock options N/A N/A N/A  ESPP 0.36 0.07 0.04  Volatility factor of the market price of the Company's common stock:  Time-based stock options 48.53 % 52.08 % 57.96 %  Performance-based stock options N/A N/A N/A  ESPP 42.33 53.73 42.50  Weighted-average expected life (years):  Time-based stock options 5.24 5.30 5.00  Performance-based stock options N/A N/A N/A  ESPP 0.25 0.25 0.25  Dividend yield 0.00 % 0.00 % 0.00 %  
Schedule Of Stock Option Activity	   Options Outstanding   Weighted- Weighted-  Average Average  Number Exercise Remaining Aggregate  of Price Per Contractual Intrinsic  Shares Share Term (Years) Value  Balance as of January 1, 2014 6,095 $ 4.14 5.66 $ 7,199  Options forfeited (705) 5.10  Options granted 1,740 4.85  Options exercised (1,233) 4.43  Balance as of December 31, 2014 5,897 $ 4.17 6.08 $ 27,066  Options forfeited (262) 5.77  Options granted 1,414 8.83  Options exercised (1,022) 4.48  Balance as of December 31, 2015 6,027 $ 5.14 6.07 $ 24,462  Options forfeited (293) 8.20  Options granted 1,510 9.79  Options exercised (1,993) 3.66  Balance as of December 31, 2016 5,251 $ 6.87 6.87 $ 21,112  Vested and expected to vest after December 31, 2016 4,847 $ 6.71 6.71 $ 20,278  Exercisable as of December 31, 2016 2,840 $ 5.56 5.53 $ 15,112 
Schedule Of RSU Activity	   RSUs and PSUs  Outstanding   Number Aggregate  of Intrinsic  Shares Value  Balance as of January 1, 2014 368 $ 1,857  Awarded 7  Vested/Released (212)  Forfeited (4)  Balance as of December 31, 2014 159 $ 1,393  Awarded 688  Vested/Released (105)  Forfeited —  Balance as of December 31, 2015 742 $ 6,822  Awarded 345  Vested/Released (151)  Forfeited (26)  Balance as of December 31, 2016 910 $ 9,825  Vested and expected to vest after December 31, 2016 775 $ 8,365  Exercisable as of December 31, 2016 (Vested and deferred) — — 

Segment Information And Geogr38

Segment Information And Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Information And Geographic Data [Abstract]
Summary Information By Operating Segment	   For the Year Ended December 31,   2016 2015 2014  Revenue:  China $ 152,563 $ 151,573 $ 130,311  Rest of the World (including the U.S. and Hong Kong) 7,533 5,684 4,479  Total net revenues $ 160,096 $ 157,257 $ 134,790  Income (loss) from operations:  China $ 57,202 $ 52,892 (2) $ 35,630 (4)  Rest of the World (including the U.S. and Hong Kong) (23,967) (1) (22,981) (3) (9,646)  Total income from operations $ 33,235 $ 29,911 $ 25,984  Non-operating income (expense):  China $ 885 $ 349 $ 412  Rest of the World (including the U.S. and Hong Kong) 13 10 (19)  Total non-operating income $ 898 $ 359 $ 393  Income (loss) before provision for income tax:  China $ 58,087 $ 53,241 $ 36,042  Rest of the World (including the U.S. and Hong Kong) (23,954) (22,971) (9,665)  Total income before provision for income tax $ 34,133 $ 30,270 $ 26,377 (1) Operating loss for the Rest of the World segment for the year ended December 31, 2016 includes upfront and milestone payments totaling $4.5 million related to the Company’s licensing arrangements. (2) Operating income for the China segment for the year ended December 31, 2015 includes upfront and milestone payments totaling $5.5 million related to the Company’s licensing arrangements. (3) Operating loss for the Rest of the World segment for the year ended December 31, 2015 includes a milestone payment totaling $2.0 million related to the Company’s licensing arrangements. Operating loss for the Rest of the World segment also includes $10.8 million of expense that the Company recorded for the year ended December 31, 2015 associated with the SEC settlement related to the Company’s investigations with the SEC and DOJ. Refer to Note 15 for further information regarding the SEC and DOJ investigations. (4) Operating income for the China segment for the year ended December 31, 2014 includes upfront payments totaling $11.0 million related to the Company’s licensing arrangements.
Long-Lived Assets By Operating Segment	  December 31,  Long-lived assets: 2016 2015  China $ 44,603 $ 46,315  Rest of the World (including the U.S. and Hong Kong) 1,562 1,783  Total long-lived assets $ 46,165 $ 48,098 

Selected Quarterly Financial 39

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Data [Abstract]
Schedule Of Selected Quarterly Financial Data	    Three Months Ended   (in thousands, except per share amounts)  March 31, June 30, September 30, December 31,  2016 2016 2016 2016  Product sales, net $ 35,320 $ 37,869 $ 39,457 $ 43,291  Promotion services revenue 1,179 1,122 1,087 771  Cost of product sales 5,813 5,712 5,585 5,788  Net income 7,864 6,338 (1) 10,116 (2) 6,411 (3)  Basic net income per share $ 0.16 $ 0.13 $ 0.20 $ 0.13  Diluted net income per share $ 0.15 $ 0.12 $ 0.19 $ 0.12      Three Months Ended   (in thousands, except per share amounts)  March 31, June 30, September 30, December 31,  2015 2015 2015 2015  Product sales, net $ 33,168 $ 37,202 $ 41,986 $ 41,973  Promotion services revenue 400 744 894 890  Cost of product sales 4,597 5,681 6,853 5,217 (5)  Net income 8,962 (4,022) (4) 11,979 12,544 (5)  Basic net income (loss) per share $ 0.18 $ (0.08) $ 0.24 $ 0.25  Diluted net income (loss) per share $ 0.17 $ (0.08) $ 0.23 $ 0.24  (1) During the three months ended June 30, 2016, the Company recorded upfront payments totaling $2.0 million in research and development expense related to its licensing arrangements. (2) During the three months ended September 30, 2016, the Company recorded a milestone payment totaling $0.2 million in research and development expense related to its licensing arrangements. (3) During the three months ended December 31, 2016, the Company recorded milestone payments totaling $2.3 million in research and development expense related to its licensing arrangements. (4) During the thre e months ended June 30, 2015, the Company recorded upfront payments totaling $5.5 million in research and development expense related to its licensing arrangements. In addition, during the three months ended June 30, 2015, the Company recorded an additional charge of $10.8 million of operating expense, in addition to the $2.0 million charge recorded in the fourth quarter of 2013, to reflect the Company’s total SEC settlement expense of $12.8 million. Refer to Note 15 for more information on the SEC and DOJ investigations. (5) During the three months ended December 31, 2015, the Company recorded a milestone payment totaling $2.0 million in research and development expense related to its licensing arrangements, and recorded a $1.1 million and $0.3 million reduction to cost of product sales and general and administrative expense, respectively, related to return of inventory and other items as part of its termination of collaboration with Cardiome. Refer also to Note 14 for more information related to this termination.

The Company And Summary Of Si40

The Company And Summary Of Significant Accounting Policies (Narrative) (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)segmentcountrysiteitemcustomershares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Available-for-sale loss	$ 0								$ 0
Product sales	43,291,000	$ 39,457,000	$ 37,869,000	$ 35,320,000	$ 41,973,000	$ 41,986,000	$ 37,202,000	$ 33,168,000	155,937,000	$ 154,329,000	$ 131,973,000
Receivable reserve	0								0
Provision for doubtful accounts										541,000
Write-downs related to inventory									34,000	0	2,099,000
Allowance for loan losses	0				0				0	0
Foreign currency transaction losses									2,200,000	400,000
Product returns reserve amount									300,000	100,000
Sales tax and surcharge costs									3,800,000	3,400,000	2,500,000
Advertising expenses									1,700,000	4,100,000	2,600,000
Accrued interest related to tax positions	1,700,000				1,700,000				1,700,000	1,700,000
Interest recognized as tax expense									$ 100,000	$ 200,000	$ 300,000
Shares excluded from the calculation of diluted net income (loss) per share | shares									2,207,440	1,151,537	3,541,071
Shares excluded from calculation of diluted net income per share due to performance conditions | shares									275,000	312,500	50,000
Number of operating segments | segment									2
General and administrative									$ 34,181,000	$ 27,897,000	$ 22,746,000
Sales and marketing									54,704,000	53,961,000	48,477,000
Income tax expense									3,404,000	807,000	1,169,000
Accrued and other current liabilities	22,796,000				32,151,000				$ 22,796,000	32,151,000
Uncertain tax position										400,000	$ 500,000	$ 400,000
ESPP [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Vesting period									3 months
One Customer [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Receivable reserve					500,000					$ 500,000
Additional Customer [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Write-down of accounts receivable					$ 500,000
Additional Customer [Member] | General And Administrative [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Provision for doubtful accounts								$ 500,000
China [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Number of partnered products to which the company markets | item									7
Sinopharm [Member] | Sales Revenue, Net [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Concentration percentage									93.00%	97.00%	94.00%
Sinopharm [Member] | Accounts Receivable [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Concentration percentage									95.00%
Accounts receivable gross	39,500,000								$ 39,500,000
Number of customers | customer									1
ZADAXIN [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Number of countries in which product is approved | country									30
Number of suppliers of key components | site									2
ZADAXIN [Member] | Sales Revenue, Net [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Product sales									$ 150,100,000	$ 146,100,000	$ 126,100,000
Concentration percentage									96.00%	95.00%	96.00%
Aggrastat Product Sales [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Inventory	$ 0								$ 0
Office Furniture and Fixtures [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Property and equipment, useful life									5 years
Office Equipment And Computer Software [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Property and equipment, useful life									3 years
Vehicle [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Property and equipment, useful life									4 years
Restatement Adjustment [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Income tax expense									$ 1,300,000
Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Business tax									5.00%
Minimum [Member] | Stock Options And RSUs [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Vesting period									1 year
Maximum [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Business tax									6.42%
Maximum [Member] | Stock Options And RSUs [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Vesting period									4 years
SPIL China [Member] | One Customer [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]
Accounts receivable gross											$ 3,000,000
Write-down of accounts receivable									$ 1,100,000
Settlement between customer and company									1,900,000
Allowance for doubtful accounts, collected									$ 500,000	$ 400,000	$ 1,000,000

The Company And Summary Of Si41

The Company And Summary Of Significant Accounting Policies (Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income Per Share Computations) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
The Company And Summary Of Significant Accounting Policies [Abstract]
Net income	$ 6,411	$ 10,116	$ 6,338	$ 7,864	$ 12,544	$ 11,979	$ (4,022)	$ 8,962	$ 30,729	$ 29,463	$ 25,208
Weighted-average shares outstanding used to compute basic net income per share									50,235	49,797	51,277
Effect of dilutive securities									2,331	2,376	1,407
Weighted-average shares outstanding used to compute diluted net income per share									52,566	52,173	52,684
Basic net income per share	$ 0.13	$ 0.20	$ 0.13	$ 0.16	$ 0.25	$ 0.24	$ (0.08)	$ 0.18	$ 0.61	$ 0.59	$ 0.49
Diluted net income per share	$ 0.12	$ 0.19	$ 0.12	$ 0.15	$ 0.24	$ 0.23	$ (0.08)	$ 0.17	$ 0.58	$ 0.56	$ 0.48

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets And Liability Measured At Fair Value On A Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	$ 20,495	$ 19,678
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	19,701	19,678
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	794
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	19,701	19,678
Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	19,701	$ 19,678
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	794
Common Stock [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	$ 794

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 5,304	$ 3,871
Work in progress	498	535
Finished goods	10,785	6,570
Total	16,587	10,976
Inventory held at distributors	$ 4,600	$ 3,300

Property And Equipment (Details

Property And Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 7,227	$ 6,812
Less accumulated depreciation	(5,225)	(4,161)
Net property and equipment	2,002	2,651
Depreciation	1,000	900	$ 900
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	14	18
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	3,363	3,172
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,513	1,281
Office Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,320	1,377
Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	936	897
Vehicle [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 81	$ 67

Investments In Third Party (Nar

Investments In Third Party (Narrative) (Details)	Sep. 09, 2016USD ($)shares	Oct. 31, 2016shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Business Acquisition [Line Items]
Cash consideration				$ 2,718,000
Fair value of common stock				794,000
Soligenix [Member]
Business Acquisition [Line Items]
Shares purchased | shares	3,529,412
Cash consideration	$ 3,000,000
Fair value of common stock	$ 2,700,000			800,000
Unrealized gains (losses) on investment				$ (1,900,000)
Research and development expense			$ 300,000
Reverse stock split conversion ratio		0.10
Number of shares after reverse stock split | shares		352,942

Loans Receivable (Narrative) (D

Loans Receivable (Narrative) (Details)	1 Months Ended	12 Months Ended
	May 31, 2013USD ($)	Dec. 31, 2016CNY (¥)loan	Dec. 31, 2016USD ($)loan	Dec. 31, 2015USD ($)loan	Dec. 31, 2014USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2014CNY (¥)	Jun. 30, 2014USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest and investment income			$ 1,062,000	$ 869,000	$ 161,000
Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum	$ 12,000,000
Allowance for loan losses			0
SPIL China [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum			11,750,000
Loan receivable			$ 11,750,000
Interest rate			7.50%
Expiration date		Sep. 26, 2017	Sep. 26, 2017
Collateralized loan, option to extend, period		2 years	2 years
Collateralized loan, extension, period		2 years	2 years
SciClone Pharmaceuticals (China) Ltd [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum | ¥		¥ 1,550,000
Loan receivable			$ 223,000				¥ 1,550,000
Interest rate			7.50%
Term		66 months	66 months
SPIL China and SciClone Pharmaceuticals (China) Ltd [Member | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Commitment agreement, number of loan agreements | loan		2	2	2
Interest and investment income			$ 900,000	$ 800,000	$ 100,000
Loans receivable, fair value			12,400,000
Loan One [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable			$ 12,000,000
Loan One [Member] | SPIL China [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable								$ 4,500,000
Loan Two [Member] | SPIL China [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable						$ 7,250,000
Expiration date		Sep. 26, 2019	Sep. 26, 2019

Goodwill (Schedule Of Changes I

Goodwill (Schedule Of Changes In Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Abstract]
Beginning balance	$ 32,979	$ 34,521	$ 35,357
Translation adjustments	(2,141)	(1,542)	(836)
Ending balance	$ 30,838	$ 32,979	$ 34,521

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Accrued SEC settlement loss (Note 15)		$ 12,826
Accrued sales and marketing expenses	$ 8,623	8,511
Accrued taxes, tax reserves and interest	5,335	4,323
Accrued compensation and benefits	5,140	4,341
Accrued professional fees	1,298	1,130
Accrued manufacturing costs	715	444
Other	1,685	576
Total	$ 22,796	$ 32,151

Commitments (Narrative) (Detail

Commitments (Narrative) (Details)	Jul. 01, 2014USD ($)ft²	Jun. 30, 2014	Dec. 31, 2013USD ($)ft²	Sep. 30, 2008USD ($)	May 31, 2007USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Finite-Lived Intangible Assets [Line Items]
Office space square footage | ft²			21,517
Base monthly rent expense			$ 120,824
Rent expense						$ 2,100,000	$ 2,100,000	$ 2,200,000
Lease Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Rent escalation, percentage					4.00%
Allowance toward cost of leasehold improvements					$ 200,000
Expansion Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Rent escalation, percentage				6.00%
Allowance toward cost of leasehold improvements				$ 500,000
Second Amendment Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Lease term			4 years
Lease renewal			5 years
Office space square footage | ft²	11,886
Base monthly rent expense	$ 51,704
Annual rent escalation per year	3.00%
China Lease [Member]
Finite-Lived Intangible Assets [Line Items]
Lease renewal		2 years

Commitments (Schedule Of Future

Commitments (Schedule Of Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements) (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments And Contingencies [Abstract]
2,017	$ 2,311
2,018	1,062
2,019	267
2,020
2,021
Total	$ 3,640

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) $ in Thousands, ¥ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016CNY (¥)	Dec. 31, 2016USD ($)	Dec. 31, 2013USD ($)
Income Tax Disclosure [Line Items]
Provision for income tax		$ 3,404	$ 807	$ 1,169
Increase (decrease) in tax expense		$ 2,600
Statutory income tax rate		34.00%
Undistributed earnings of foreign subsidiaries						$ 211,000
Dividend distributions to parent company from foreign subsidiaries to address liquidity needs		$ 10,000
Special dividend distribution repatriated from foreign subsidiary	$ 12,800
Deferred tax assets, change in valuation allowance		(1,400)	1,400	3,400
US federal net operating loss carryforwards						112,900
Research and development, orphan drug and investment tax credit carryforwards gross amount						12,300
State net operating loss carryforwards						25,900
State research and development tax credit carryforwards						2,200
Unrecognized tax benefits	5,470		5,470	$ 5,876		5,783	$ 6,138
Unrecognized tax benefits that would impact effective tax rate						2,200
Unrecognized tax benefits, amount offset by valuation allowance						3,600
Accrued interest related to tax positions	$ 1,700		$ 1,700			$ 1,700
Relates to Stock Option Deductions When Recognized [Member]
Income Tax Disclosure [Line Items]
Deferred tax assets, change in valuation allowance		4,400
Restatement Adjustment [Member]
Income Tax Disclosure [Line Items]
Provision for income tax		$ 1,300
NovaMed [Member]
Income Tax Disclosure [Line Items]
Foreign net operating loss carryforwards | ¥					¥ 40.8
China [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate		25.00%	25.00%	25.00%
Income tax examination, period		5 years
Minimum [Member] | Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2020
Minimum [Member] | U. S. Federal Research and Development, Orphan Drug and Investment Tax Credit [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2018
Minimum [Member] | Foreign Tax Authority [Member] | NovaMed [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2019
Minimum [Member] | State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2017
Maximum [Member] | Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2035
Maximum [Member] | U. S. Federal Research and Development, Orphan Drug and Investment Tax Credit [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2036
Maximum [Member] | Foreign Tax Authority [Member] | NovaMed [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2021
Maximum [Member] | State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, expiration		Dec. 31, 2030

Income Taxes (Schedule Of Domes

Income Taxes (Schedule Of Domestic And Foreign Components Of Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Domestic	$ (8,363)	$ (17,017)	$ (8,496)
Foreign	42,496	47,287	34,873
Income before provision for income tax	$ 34,133	$ 30,270	$ 26,377

Income Taxes (Schedule of Effec

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Tax at federal statutory rate	$ 11,605	$ 10,382	$ 8,968
Foreign income taxed at different rates	(11,712)	(15,210)	(10,788)
Federal tax effect of dividend from foreign subsidiary	2,999	4,317
Effect of uncertain tax positions	667	(126)	127
Change in valuation allowance	(199)	1,092	2,672
Stock-based compensation	(604)	(86)	2
Non deductible expenses	247	189	189
Other	401	249	(1)
Provision for income tax	$ 3,404	$ 807	$ 1,169

Income Taxes (Schedule Of Compo

Income Taxes (Schedule Of Components Of Income Tax Expense (Benefit)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Federal
State	1	1	1
Foreign	3,103	793	1,489
Total current	3,104	794	1,490
Federal
State
Foreign	300	13	(321)
Total deferred	300	13	(321)
Provision for income tax	$ 3,404	$ 807	$ 1,169

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Net operating loss carryforwards	$ 36,938	$ 38,679
Research and development credit carryforwards	10,719	10,650
Intangibles	530	382
Other	2,543	2,692
Gross deferred tax assets	50,730	52,403
Valuation allowance	(50,730)	(52,104)
Total deferred tax assets		299
Other
Total deferred tax liabilities
Net deferred tax assets		$ 299

Income Taxes (Schedule Of Unrec

Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Balance beginning of period	$ 5,470	$ 5,876	$ 6,138
Additions for current year items	25	14	32
Additions for prior year items (see Note 1)	1,009
Lapse of statute of limitations	(604)	(288)	(206)
Changes for foreign currency translation	(117)	(132)	(88)
Balance end of period	$ 5,783	$ 5,470	$ 5,876

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	12 Months Ended			24 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Oct. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses recognized	$ 6,433,000	$ 4,441,000	$ 3,465,000
Share-based compensation, income tax benefit	$ 0
Share repurchase program, amount authorized					$ 80,500,000
Share repurchase program, expiration date	Dec. 31, 2015
Stock repurchased and retired, shares		1,526,306	3,822,434
Stock repurchased and retired, value		$ 12,811,000	$ 24,400,000
Stock repurchased, value				$ 78,100,000
Equity Incentive Plan [Member] | 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	6,550,000
Award expiration	10 years
Vesting period	4 years
Equity Incentive Plan [Member] | 2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	13,600,000
Award expiration	10 years
Vesting period	4 years
Shares reserved for future issuance	0
Equity Incentive Plan [Member] | 2004 Director Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	1,765,000
Award expiration	10 years
Shares reserved for future issuance	0
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 months
Shares reserved for future issuance	2,400,000
Shares available for issuance	2,398,138
Stock plan maximum percentage withheld by employee	15.00%
Common stock that can be purchased, value	$ 6,250
Common stock shares that can be purchased	999
Offering period	3 months
Stock discount percentage	85.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options per share	$ 4.33	$ 4.18	$ 2.43
Intrinsic value of options at exercise	$ 14,600,000	$ 4,700,000	$ 2,400,000	$ 4,700,000
Estimated fair value of shares vested	4,400,000	3,900,000	3,200,000
Unrecognized compensation expense, net of forfeitures	$ 6,600,000
Compensation expense weighted average period recognized	2 years 4 months 28 days
Cash from stock option exercise	$ 5,600,000	$ 4,600,000	$ 5,500,000
Value of shares withheld to cover taxes and exercise price	$ 3,400,000
Shares withheld to cover taxes and exercise price	411,407
Common stock, option exercises, shares	1,993,000	1,022,000	1,233,000
Performance-Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation costs	$ 0	$ 20,000	$ 100,000
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options at exercise
RSUs [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	25.00%
PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration	10 years
Share based compensation costs	$ 300,000	$ 100,000	$ 0
RSUs and PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options per share	$ 10.04	$ 8.95	$ 4.52
Estimated fair value of shares vested	$ 1,600,000	$ 1,000,000	$ 1,000,000
Unrecognized compensation expense, net of forfeitures	$ 3,700,000
Unrecognized compensation expense, weighted-average remaining period for recognition, in years	1 year 3 months 22 days
Minimum [Member] | RSUs [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member] | Equity Incentive Plan [Member] | 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of addtional shares	3,000,000
Maximum [Member] | RSUs [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses recognized	$ 200,000	$ 100,000	$ 100,000

Stockholders' Equity (Stock-Bas

Stockholders' Equity (Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	$ 6,433	$ 4,441	$ 3,465
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	984	869	1,031
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	336	210	104
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	$ 5,113	$ 3,362	$ 2,330

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Valuation Assumptions Used For Stock Options And ESPP Plans) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Dividend yield	0.00%	0.00%	0.00%
Stock Options [Member]
Risk-free interest rate	1.41%	1.52%	1.61%
Volatility factor of the market price of common stock	48.53%	52.08%	57.96%
Weighted-average expected life (years)	5 years 2 months 27 days	5 years 3 months 18 days	5 years
ESPP [Member]
Risk-free interest rate	0.36%	0.07%	0.04%
Volatility factor of the market price of common stock	42.33%	53.73%	42.50%
Weighted-average expected life (years)	3 months	3 months	3 months

Stockholders' Equity (Schedul60

Stockholders' Equity (Schedule Of Stock Option Activity) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares, Beginning Balance	6,027	5,897	6,095
Number of Shares, Options forfeited	(293)	(262)	(705)
Number of Shares, Options granted	1,510	1,414	1,740
Number of Shares, Options exercised	(1,993)	(1,022)	(1,233)
Number of Shares, Ending Balance	5,251	6,027	5,897	6,095
Number of Shares, Vested and expected to vest after December 31, 2016	4,847
Number of Shares, Exercisable as of December 31, 2016	2,840
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 5.14	$ 4.17	$ 4.14
Weighted-Average Exercise Price Per Share, Options forfeited	8.20	5.77	5.10
Weighted-Average Exercise Price Per Share, Options granted	9.79	8.83	4.85
Weighted-Average Exercise Price Per Share, Options exercised	3.66	4.48	4.43
Weighted-Average Exercise Price Per Share, Ending Balance	6.87	$ 5.14	$ 4.17	$ 4.14
Weighted-Average Exercise Price Per Share, Vested and expected to vest after December 31, 2016	6.71
Weighted-Average Exercise Price Per Share, Exercisable as of December 31, 2016	$ 5.56
Weighted-Average Remaining Contractual Term (Years), Options outstanding	6 years 10 months 13 days	6 years 26 days	6 years 29 days	5 years 7 months 28 days
Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest after December 31, 2016	6 years 8 months 16 days
Weighted-Average Remaining Contractual Term (Years), Exercisable as of December 31, 2016	5 years 6 months 11 days
Aggregate Intrinsic Value, Balance	$ 21,112	$ 24,462	$ 27,066	$ 7,199
Aggregate Intrinsic Value, Vested and expected to vest after December 31, 2016	20,278
Aggregate Intrinsic Value, Exercisable as of December 31, 2016	$ 15,112

Stockholders' Equity (Schedul61

Stockholders' Equity (Schedule Of RSU Activity) (Details) - RSUs [Member] - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares, Beginning Balance	742	159	368
Number of Shares, Options awarded	345	688	7
Number of Shares, Options Vested/Released	(151)	(105)	(212)
Number of Shares, Options forfeited	(26)		(4)
Number of Shares, Ending Balance	910	742	159
Number of Shares, Vested and expected to vest after December 31, 2016	775
Number of Shares, Exercisable as of December 31, 2016 (Vested and deferred)
Aggregate Intrinsic Value, Balance	$ 9,825	$ 6,822	$ 1,393	$ 1,857
Aggregate Intrinsic Value, Vested and expected to vest after December 31, 2016	8,365
Aggregate Intrinsic Value, Exercisable as of December 31, 2016 (Vested and deferred)

401(k) Plan (Narrative) (Detail

401(k) Plan (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
401(k) Plan [Abstract]
Company 401k match, percentage	50.00%
Company contributions	$ 0.2	$ 0.2	$ 0.1

Licensing Agreements (Narrative

Licensing Agreements (Narrative) (Details) $ in Millions	May 13, 2013USD ($)	Dec. 31, 2014item	May 31, 2013USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	May 31, 2015USD ($)
Upfront and regulatory milestone payments				$ 2.3	$ 2		$ 0.2	$ 2	$ 5.5
Research and development expense related to in-licensing deals				$ 4.5	$ 7.5	$ 11
Theravance Biopharma [Member]
Upfront and regulatory milestone payments										$ 6
The Medicines Company [Member]
Number of products | item		2
Commitment agreement payment amount						$ 50.5
Zensun [Member]
Commitment agreement payment amount	$ 18.5
Commitment agreement additional payment amount	10
Commitment agreement further payments upon approval for new indications of product	$ 25
Collateralized loan amount, maximum			$ 12

Termination Of Collaboration 64

Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”) (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Aug. 31, 2015	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues					$ 160,096,000	$ 157,257,000	$ 134,790,000
Product returns reserve amount					300,000	100,000
Inventories			$ 10,976,000	$ 10,976,000	$ 16,587,000	10,976,000
Cardiome [Member]
Transition payments to be received	$ 750,000
Transition payments to be received, period	1 year
Transition payments received		$ 300,000		450,000
Payment received for repurchased inventory			1,100,000
Reduction in cost of product sales			1,100,000
Aggrastat Product Sales [Member] | Cardiome [Member]
Revenues						1,800,000	$ 1,100,000
Product returns reserve amount						600,000
Inventories			$ 0	$ 0		$ 0

Contingencies (Narrative) (Deta

Contingencies (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 29, 2016	Jun. 30, 2015	Dec. 31, 2013	Dec. 31, 2015	Feb. 24, 2017	Oct. 07, 2015
Contingencies [Line Items]
Estimated SEC/DOJ investigation loss		$ 10,800,000	$ 2,000,000	$ 10,826,000
SEC settlement loss	$ 12,800,000			12,800,000
Escrow deposit				$ 12,826,000		$ 12,800,000
NovaMed Shanghai [Member] | Subsequent Event [Member]
Contingencies [Line Items]
Settlement agreement receivable					$ 83,333

Credit Facility (Narrative) (De

Credit Facility (Narrative) (Details) ¥ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2013CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Line of Credit Facility [Line Items]
Debt financing facility, expiration date		Nov. 30, 2014
Interest paid		$ 48,000
Shanghai Pudong Development Bank Co. Ltd. [Member]
Line of Credit Facility [Line Items]
Debt financing facility, maximum borrowing capacity	¥ 15		$ 2,400,000
Effective interest rate		6.44%
Shanghai Pudong Development Bank Co. Ltd. [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Percentage points added to reference rate	15.00%
NovaMed [Member]
Line of Credit Facility [Line Items]
Debt financing facility, maximum borrowing capacity	¥ 10		$ 1,600,000

Segment Information And Geogr67

Segment Information And Geographic Data (Summary Information By Operating Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2015	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenue			$ 160,096	$ 157,257	$ 134,790
Income (loss) from operations			33,235	29,911	25,984
Non-operating income (expense), net			898	359	393
Income (loss) before provision for income tax			34,133	30,270	26,377
Upfront and regulatory milestone payments	$ 5,500		2,300	2,000		$ 200	$ 2,000
SEC settlement expense (Note 15)	$ 10,800	$ 2,000		10,826
China [Member]
Segment Reporting Information [Line Items]
Revenue			152,563	151,573	130,311
Income (loss) from operations			57,202	52,892	35,630
Non-operating income (expense), net			885	349	412
Income (loss) before provision for income tax			58,087	53,241	36,042
Upfront and regulatory milestone payments				5,500	11,000
Rest of the World (including the U.S. and Hong Kong) [Member]
Segment Reporting Information [Line Items]
Revenue			7,533	5,684	4,479
Income (loss) from operations			(23,967)	(22,981)	(9,646)
Non-operating income (expense), net			13	10	(19)
Income (loss) before provision for income tax			(23,954)	(22,971)	$ (9,665)
Upfront and regulatory milestone payments			$ 4,500	2,000
SEC settlement expense (Note 15)				$ 10,800

Segment Information And Geogr68

Segment Information And Geographic Data (Long-Lived Assets By Operating Segment) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Long-lived assets	$ 46,165	$ 48,098
China [Member]
Segment Reporting Information [Line Items]
Long-lived assets	44,603	46,315
Rest of the World (including the U.S. and Hong Kong) [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 1,562	$ 1,783

Selected Quarterly Financial 69

Selected Quarterly Financial Data (Schedule Of Selected Quarterly Financial Data) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended									12 Months Ended
	Feb. 29, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Product sales, net		$ 43,291	$ 39,457	$ 37,869	$ 35,320	$ 41,973	$ 41,986	$ 37,202	$ 33,168		$ 155,937	$ 154,329	$ 131,973
Promotion services revenue		771	1,087	1,122	1,179	890	894	744	400		4,159	2,928	2,817
Cost of product sales		5,788	5,585	5,712	5,813	5,217	6,853	5,681	4,597		22,898	22,348	23,002
Net income		$ 6,411	$ 10,116	$ 6,338	$ 7,864	$ 12,544	$ 11,979	$ (4,022)	$ 8,962		$ 30,729	$ 29,463	$ 25,208
Basic net income per share		$ 0.13	$ 0.20	$ 0.13	$ 0.16	$ 0.25	$ 0.24	$ (0.08)	$ 0.18		$ 0.61	$ 0.59	$ 0.49
Diluted net income per share		$ 0.12	$ 0.19	$ 0.12	$ 0.15	$ 0.24	$ 0.23	$ (0.08)	$ 0.17		$ 0.58	$ 0.56	$ 0.48
SEC settlement expense (Note 15)								$ 10,800		$ 2,000		$ 10,826
SEC settlement loss	$ 12,800											12,800
Upfront and regulatory milestone payments		$ 2,300	$ 200	$ 2,000		$ 2,000		$ 5,500			$ 2,300	$ 2,000
Cardiome [Member]
Payment received for repurchased inventory						1,100
Reduction in general and administraive expense						$ 300

Subsequent Event (Details)

Subsequent Event (Details)	Feb. 24, 2017USD ($)
Subsequent Event [Member] | NovaMed Shanghai [Member]
Subsequent Event [Line Items]
Settlement agreement receivable	$ 83,333

Schedule II - Valuation And Q71

Schedule II - Valuation And Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Receivables Reserve [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ (594)	$ (998)	$ (3,587)
Charges for Amount Reserved		(541)
Deductions for Amounts Recovered	500	400	1,500
Deductions for Amounts Written Off	94	545	1,089
Balance at End of Period		(594)	(998)
Reserve For Product Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	(134)	(66)
Charges for Amount Reserved	(155)	(134)	(66)
Deductions for Amounts Recovered
Deductions for Amounts Written Off
Deductions for Amounts Paid		66
Balance at End of Period	$ (289)	$ (134)	$ (66)